FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packagehl7.fhir.uv.clinical-study-protocol
Resource TypeCodeSystem
IdCodeSystem-ncit-cs.json
FHIR VersionR6
Sourcehttps://build.fhir.org/ig/HL7/vulcan-udp-ig/CodeSystem-ncit-cs.html
URLhttp://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
Version1.0.0-ballot2
Statusactive
Date2026-03-30T16:32:09+00:00
NameNCIT
TitleFragment of NCIT Code System
Realmuv
Authorityhl7
DescriptionThis is a fragment from the NCI Thesaurus covering codes used by ICH M11 Value Sets. These should all be moved into tx.fhir.org but are included here for testing and validation.
Contentfragment

Resources that use this resource

CodeSystem
hl7.fhir.us.pq-cmc-fda#currentcmc-hierarchy-supplementPQ-CMC-FDA NCIt Hierarchy Supplement
ValueSet
hl7.fhir.us.icsr-ae-reporting#currentPatientMilitaryStatusPatient Military Status
hl7.fhir.us.mcode#currentmcode-all-risk-assessment-value-vsAcute Lymphoblastic Leukemia (ALL) Risk Assessment Value Set
hl7.fhir.us.mcode#currentmcode-binet-stage-value-vsBinet Stage Value Set
hl7.fhir.us.mcode#currentmcode-cancer-stage-type-vsCancer Stage Type Value Set
hl7.fhir.us.mcode#currentmcode-cancer-stage-value-vsCancer Stage Value Set
hl7.fhir.us.mcode#currentmcode-cancer-staging-method-vsCancer Staging Method Value Set
hl7.fhir.us.mcode#currentmcode-deauville-scale-vsDeauville Scale Value Set
hl7.fhir.us.mcode#currentmcode-figo-stage-value-vsFIGO Stage Value Set
hl7.fhir.us.mcode#currentmcode-international-retinoblastoma-stage-value-vsInternational Retinoblastoma Stage Value
hl7.fhir.us.mcode#currentmcode-lansky-play-performance-vsLansky Play Performance Status VS
hl7.fhir.us.mcode#currentmcode-lymphoma-stage-value-vsLymphoma Stage Value Set
hl7.fhir.us.mcode#currentmcode-lymphoma-staging-method-vsLymphoma Staging System Value Set
hl7.fhir.us.mcode#currentmcode-myeloma-iss-stage-value-vsInternational Staging System (ISS) for Myeloma Stage Value Set
hl7.fhir.us.mcode#currentmcode-myeloma-riss-stage-value-vsRevised International Staging System (ISS) for Multiple Myeloma Stage Value Set
hl7.fhir.us.mcode#currentmcode-neuroblastoma-INRGSS-value-vsInternational Neuroblastoma Risk Group Staging System (INRGSS) for Neuroblastoma Risk Assessment Value Set
hl7.fhir.us.mcode#currentmcode-pretext-stage-value-vsPRETEXT Stage Value
hl7.fhir.us.mcode#currentmcode-rai-stage-value-vsRai Stage Value Set
hl7.fhir.us.mcode#currentmcode-rai-staging-method-vsRai Staging System Value Set
hl7.fhir.us.mcode#currentmcode-rhabdomyosarcoma-assessment-value-vsRhabdomyosarcoma Assessment Value Set
hl7.fhir.us.mcode#currentmcode-rhabdomyosarcoma-clinical-group-value-vsRhabdomyosarcoma Clinical Group Value
hl7.fhir.us.mcode#currentmcode-risk-assessment-type-vsRisk Assessment Type Value Set
hl7.fhir.us.mcode#currentmcode-risk-assessment-vsRisk Assessment Value Set
hl7.fhir.us.mcode#currentmcode-tnm-staging-method-vsTNM Staging Method Value Set
hl7.terminology#currentadverse-event-clinical-research-causality-relatednessAdverse Event Clinical Research Causality Relatedness
hl7.terminology#currentadverse-event-clinical-research-gradesAdverse Event Clinical Research Grades
hl7.terminology#currentadverse-event-clinical-research-outcomesAdverse Event Clinical Research Outcomes
hl7.terminology#currentadverse-event-clinical-research-seriousness-criteriaAdverse Event Clinical Research Seriousness Criteria
hl7.terminology#currentresearch-subject-milestonesResearch Subject Milestones
hl7.fhir.uv.emedicinal-product-info#currentpropertyColorColor of the product
hl7.fhir.uv.emedicinal-product-info#currentpropertyFlavorFlavor of the product
hl7.fhir.uv.emedicinal-product-info#currentpropertyShapeShape of the product
hl7.fhir.us.codex-radiation-therapy#currentcodexrt-radiotherapy-adverse-event-termVSAdverse Event Terms Value Set
hl7.fhir.us.spl#currentvalueset-businessOperationQualifiersBusiness Operation Qualifiers
hl7.fhir.us.spl#currentvalueset-establishmentBusinessOperationsEstablishment Business Operations
hl7.fhir.us.spl#currentvalueset-gdufaFacilityBusinessOperationQualifiersGDUFA Facility Business Operation Qualifiers
hl7.fhir.us.spl#currentvalueset-gdufaFacilityBusinessOperationsGDUFA Facility Business Operations
hl7.fhir.us.spl#currentvalueset-labelerBusinessOperationsLabeler Business Operations
hl7.fhir.us.spl#currentvalueset-splColorSPL Color
hl7.fhir.us.spl#currentvalueset-splComboProductTypeSPL Combo Product Type
hl7.fhir.us.spl#currentvalueset-splDoseFormSPL Dose Form
hl7.fhir.us.spl#currentvalueset-splFlavorSPL Flavor
hl7.fhir.us.spl#currentvalueset-splMarketingCategoriesSPL Marketing Categories
hl7.fhir.us.spl#currentvalueset-splOperationTypeSPL Operation Type
hl7.fhir.us.spl#currentvalueset-splPackageTypesSPL Package Types
hl7.fhir.us.spl#currentvalueset-splRouteOfAdministrationSPL Route of Administration
hl7.fhir.us.spl#currentvalueset-splShapeSPL Shape
hl7.fhir.us.spl#currentvalueset-splSpecialMeasuresSPL Special Measures
hl7.fhir.us.pq-cmc-fda#currentcapsule-classification-categoryCapsule Shell Classification Terminology
hl7.fhir.us.pq-cmc-fda#currentcmc-product-name-types-vsProduct Name Types Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-batch-utilization-terminologyBatch utilization Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-chemical-structure-datafile-type-terminologyChemical Structure Data File Type Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-closure-type-terminologyClosure Type Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-coating-purposeCoating Purpose Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-container-type-terminologyContainer Type Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-drug-product-component-function-category-terminologyDrug Product Component Function Category Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-excipient-function-terminologyExcipient Function Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-impurity-classification-terminologyImpurity Classification Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-manufactured-dose-form-terminologyManufactured Dose Form Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-product-part-ingredient-physical-locationIngredient Location Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-product-part-typeProduct Part Type Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-quality-benchmark-terminologyQuality Benchmark Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-release-mechanismRelease Mechanism Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-release-profileRelease Profile Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-representation-typesRepresentation Types
hl7.fhir.us.pq-cmc-fda#currentpqcmc-source-type-terminologySource Type Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-specification-status-terminologySpecification Status Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-specification-type-terminologySpecification Type Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-strength-type-terminologyStrength Type Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-substance-name-typeSubstance Name Type
hl7.fhir.us.pq-cmc-fda#currentpqcmc-test-category-terminologyTest Category Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-test-method-origin-terminologyTest Method Origin Terminology
hl7.fhir.us.pq-cmc-fda#currentpqcmc-test-usage-terminologyTest Usage Terminology
hl7.fhir.us.pq-cmc-fda#currentspl-drug-route-of-administration-terminologyDrug Route Of Administration Terminology
hl7.fhir.us.pq-cmc-fda#currentspl-pharmaceutical-dosage-form-terminologyPharmaceutical Dosage Form Terminology
hl7.fhir.us.pq-cmc-fda#currentsubstance-classificationSubstance Classification
hl7.fhir.uv.clinical-study-protocol#currentm11-amendment-details-statement-vsICH M11 Amendment Details Statement Value Set Terminology
hl7.fhir.uv.clinical-study-protocol#currentm11-amendment-scope-enrollment-vsICH M11 Amendment Scope Enrollment Description Value Set Terminology
hl7.fhir.uv.clinical-study-protocol#currentm11-blinded-roles-vsICH M11 Trial Blinding Role Value Set Terminology
hl7.fhir.uv.clinical-study-protocol#currentm11-phase-vsICH M11 Trial Phase Value Set Terminology
hl7.fhir.uv.clinical-study-protocol#currentm11-study-amendment-reason-vsICH M11 Reason for Amendment Value Set Terminology
hl7.fhir.uv.clinical-study-protocol#currentm11-study-amendment-scope-vsICH M11 Amendment Scope Value Set Terminology
hl7.fhir.uv.clinical-study-protocol#currentm11-yes-no-vsICH M11 No Yes Value Set Terminology
hl7.fhir.uv.clinical-study-protocol#currentudp-address-purpose-type-vsUDP Address Purpose Type Value Set
hl7.fhir.uv.clinical-study-protocol#currentudp-identifier-type-vsUDP Identifier Type Value Set
hl7.fhir.uv.clinical-study-protocol#currentudp-narrative-elements-vsUDP Narrative Elements Value Set
hl7.fhir.uv.clinical-study-protocol#currentudp-party-role-type-vsUDP Party Role Type Value Set
hl7.fhir.uv.clinical-study-protocol#currentudp-related-artifact-type-vsUDP Related Artifact Type Value Set
hl7.fhir.uv.clinical-study-protocol#currentudp-section-codes-vsUDP Section Codes Value Set
hl7.fhir.uv.clinical-study-protocol#currentudp-study-title-type-vsUDP Study Title Type Value Set
hl7.fhir.uv.genomics-reporting#currentmolecular-biomarker-code-vsMolecular Biomarker Codes
hl7.fhir.uv.ae-research-backport-ig.r4b#1.0.0-ballotadverse-event-causality-related-vsCausality Relatedness values
hl7.fhir.uv.ae-research-backport-ig.r4b#1.0.0-ballotadverse-event-outcome-clinical-research-vsAdverse Event Clinical Research Outcomes
hl7.fhir.uv.ae-research-backport-ig.r4b#1.0.0-ballotadverse-event-seriousness-criteria-vsAdverse Event Seriousness Criteria
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-cd-datacollected-nciNFDI4Health Data Collected [NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-cd-information-sources-nci-localNFDI4Health Data Collected [NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-id-type-nci-localNFDI4Health VS MDS ID Type [NCI, local]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-identifier-type-related-artifact-nci-localNFDI4Health VS MDS Identifier Type Related Artifact [NCI, local]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-mortality-data-nciNFDI4Health VS MDS Mortality Data [NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-ne-instrument-nci-localNFDI4Health NE Instrument [NCI, Local]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-ne-mode-nci-msh-localNFDI4Health NE Mode [NCI, MeSH, Local]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-organisational-roles-nci-localNFDI4Health VS MDS Organisational Roles [NCI, local]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-personal-roles-nci-localNFDI4Health VS MDS Personal Roles [NCI, local]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-population-coverage-nciNFDI4Health VS MDS Population Coverage [NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-resource-type-general-nci-msh-localNFDI4Health VS MDS Resource Type General [NCI, MSH, local]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-resource-type-nci-localNFDI4Health VS MDS Resource Type [NCI, Local]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-allocation-nciNFDI4Health VS MDS Study Allocation [NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-arm-group-type-nciNFDI4Health VS MDS Study Arm Group Type [NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-assessments-sct-nciNFDI4Health VS MDS Study Assessments [SCT, NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-biospecimen-retention-nciNFDI4Health VS MDS Study Biospecimen Retention [NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-conditions-classification-nci-localNFDI4Health VS MDS Study Conditions Classification [NCI, Local]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-data-sharing-plan-ds-sct-nciNFDI4Health VS MDS Study Data Sharing Plan Datashield [SCT, NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-data-sharing-plan-sup-inf-nci-localNFDI4Health VS MDS Study Data Sharing Plan Supporting Information [NCI, local]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-data-sources-general-nci-localNFDI4Health VS MDS Study Data Sources General [NCI, local]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-data-sources-imaging-nciNFDI4Health VS MDS Study Data Sources Imaging [NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-data-sources-omics-nciNFDI4Health VS MDS Study Data Sources Omics [NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-ds-biosamples-sct-nciNFDI4Health VS MDS Study Data Sources Biosamples [SCT, NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-ethics-committee-approval-nci-localNFDI4Health VS MDS Study Ethics Commitee Approval [NCI, local]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-exposure-type-nciNFDI4Health VS MDS Study Exposure Type [NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-group-characteristics-nciNFDI4Health VS MDS Study Group Characteristics [NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-intervention-type-nciNFDI4Health VS MDS Study Intervention Type [NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-masking-roles-nci-localNFDI4Health VS MDS Study Masking Roles [NCI, local]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-outcome-type-nciNFDI4Health VS MDS Study Outcome Type [NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-overall-status-nci-localNFDI4Health VS MDS Study Overall Status [NCI, Local]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-phase-nciNFDI4Health VS MDS Study Phase [NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-primary-design-nciNFDI4Health VS MDS Study Primary Design [NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-primary-purpose-hl7-nciNFDI4Health VS MDS Study Primary Purpose [HL7, NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-recruitment-register-nci-sct-localNFDI4Health VS MDS Study Recruitment Register [NCI, SCT, Local]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-sampling-method-nci-localNFDI4Health VS MDS Study Sampling Method [NCI, local]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-sampling-method-non-prob-nci-localNFDI4Health VS MDS Study Sampling Method Non Probability [NCI, local]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-sampling-prob-method-nci-localNFDI4Health VS MDS Study Sampling Probability Method [NCI, Local]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-time-perspectives-nciNFDI4Health VS MDS Study Time Perspectives [NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-type-interventional-nciNFDI4Health VS MDS Study Type Interventional [NCI]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-study-type-non-interventional-nci-msh-localNFDI4Health VS MDS Study Type Non Interventional [NCI, MSH, local]
de.nfdi4health.mds#2.1.0nfdi4health-vs-mds-yes-no-undecided-nciNFDI4Health VS MDS Yes, No, Undecided [ NCI]
hl7.fhir.uv.pharmaceutical-research-protocol#1.0.0-ballotcdisc-yes-no-vsCDISC Yes No Unknown Not Applicable Value Set
hl7.fhir.uv.pharmaceutical-research-protocol#1.0.0-ballotddf-study-title-type-vsCDISC DDF Study Title Type Value Set
hl7.fhir.uv.pharmaceutical-research-protocol#1.0.0-ballotm11-amendment-scope-enrollment-vsStudy Amendment Scope Enrollment Value Set
hl7.fhir.uv.pharmaceutical-research-protocol#1.0.0-ballotm11-identifier-type-vsM11 Identifier Type Value Set
hl7.fhir.uv.pharmaceutical-research-protocol#1.0.0-ballotm11-phase-vsM11 Phase Value Set
hl7.fhir.uv.pharmaceutical-research-protocol#1.0.0-ballotm11-section-codes-vsM11 Section Codes Value Set
hl7.fhir.uv.pharmaceutical-research-protocol#1.0.0-ballotm11-study-amendment-reason-vsStudy Amendment Reason Value Set
hl7.fhir.uv.pharmaceutical-research-protocol#1.0.0-ballotm11-study-amendment-scope-vsStudy Amendment Scope Value Set
hl7.fhir.uv.pharmaceutical-research-protocol#1.0.0-ballotnci-study-role-vsNCI Study Role Value Set
de.medizininformatikinitiative.kerndatensatz.onkologie#2026.0.3-rc.1mii-vs-onko-weitere-klassifikationenMII Value Set Onkologie - Weitere Klassifikationen
de.medizininformatikinitiative.use-case.omi#0.3.25deid-parameter-namesDe-identification Parameter Names
de.medizininformatikinitiative.use-case.omi#0.3.25device-note-typesDevice Note Type Codes
de.uk-koeln.nngm.form#1.0.0anforderung-liquidBiopsyValueSet - nNGM - Anforderung Liquid Biopsy
de.uk-koeln.nngm.form#1.0.0anforderung-molekularpathologieValueSet - nNGM - Anforderung Molekularpathologie
de.uk-koeln.nngm.form#1.0.0MaterialTypValueSet - nNGM - MaterialTyp
de.uk-koeln.nngm.form#1.0.0tki-resistenzValueSet - nNGM - TKI Resistenz
de.j-med.myjmed#0.1.0ncit-ctcae-event-vsNCIt CTCAE Event ValueSet (MyJMed)
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1021.30AdministrationUnitDoseForm
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1021.46Device Magnetic resonance (MR) Safety
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1021.47Device Latex Safety
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1021.48Implantable Device Status
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1032.292Non pharmacologic treatments for chronic pain NCI
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1032.36Non pharmacologic treatments for chronic pain
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.100MMR Proficient
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.11Estrogen Receptor Test for Orserdu
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.116Localized Bladder Cancer Staging
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.119Localized Bladder Cancer T Stage
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.128FGFR3 Gene
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.13HER2 Negative
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.131FGFR3 Gene Interpretation Positive NCI
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.133FGFR3 Gene Interpretation Positive
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.135FGFR3 Gene Interpretation Negative NCI
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.137FGFR3 Gene Interpretation Negative
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.138FGFR3 Molecular Variants
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.190Localized NSCLC Stage Group NCIM
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.192Localized NSCLC Stage Group
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.198EGFR Gene
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.203EGFR Generic Molecular Variant NCIM
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.206EGFR Molecular Variants Osimertinib PM
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.214Radiation Treatment Delivery NCIM
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.216Radiation Treatment Delivery
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.227MET Exon 14 skipping molecular variant
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.235ROS1 Repotrectinib Molecular Variants
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.237ROS1 Negative (geneinterpretation) NCI
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.238ROS1 Negative (geneinterpretation) SNOMEDCT,NCI
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.240ROS1 results (HGNC)
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.246RET Negative (geneinterpretaion) NCI
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.247RET Negative (geneinterpretaion) SNOMEDCT,NCI
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.248RET Fusion Molecular Variants
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.25ESR1 Gene Test
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.26ESR1 Genetic Mutation
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.260ALK Positive (geneinterpretation) NCI
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.261ALK Positive (geneinterpretation) SNOMEDCT NCI
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.263ALK Negative (geneinterpretation) NCI
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.264ALK Negative (geneinterpretation) SNOMEDCT NCI
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.277Extensive SCLC Stage Group NCIM
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.278Extensive SCLC Stage Group
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.28Her2 Negative
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.30HER2 Positive
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.305HER2 Negative (geneinterpretation/Labtestvalue) NCI
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.307HER2 Negative (geneinterpretation/Labtestvalue)
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.311Localized_Solid_Cancer_Stage Group NCIM
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.313Localized_Solid_Cancer_Stage Group
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.314Locally_Advanced_Solid_Cancer_Stage Group NCIM
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.315Locally_Advanced_Solid_Cancer_Stage Group
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.316Metastatic_Solid_Cancer_Stage Group NCIM
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.317Metastatic_Solid_Cancer_Stage Group
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.319Solid Cancer T Stage NCI
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.32HER2 Positive
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.320Solid Cancer T Stage codes
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.325RET fusion Molecular Variants_Solid_Cancer
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.344PTEN_gene
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.346PIK3CA_gene
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.348AKTI_gene
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.350Progesterone_receptor_gene
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.352Estrogen_receptor_gene
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.359HER2_IHC_test_Gene
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.372HER2 test_gene
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.416KRAS_G12C_MV
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.429Localized_Endometerial_Stage Group NCIM
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.460Localized_Endometerial_Stage Group_SNOMED/NCIM
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.465NTRK Repotrectinib Molecular Variants
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.55MSI High
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.57Early Stage IIB or lower
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.60MMR Deficient
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.61Stage IIB or lower and limited
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.63Stage III or higher
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.64Stage III or higher
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.66Staging Unknown
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.67Staging Unknown
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.84RAS Gene Interpretation Negative NCM
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.85RAS Gene Negative
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.9ER Test for Orserdu
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.91MSI High NCI
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.94MSI Low NCI
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.95MSI Low
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.96MMR Deficient NCI
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1260.99MMR Proficient NCI
us.nlm.vsac#0.24.02.16.840.1.113762.1.4.1267.22Route of Administration of Therapeutic Agents
us.nlm.vsac#0.24.02.16.840.1.113883.3.88.12.3221.8.11Medication Product Form
us.nlm.vsac#0.24.02.16.840.1.113883.3.88.12.3221.8.7SPL Drug Route of Administration Terminology
ans.fr.terminologies#1.7.0jdv-methode-de-mesure-acuite-visuelle-cisisJDV Methode De Mesure Acuite Visuelle CISIS
ans.fr.terminologies#1.7.0jdv-motif-echographie-cisisJDV Motif Echographie CISIS
ans.fr.terminologies#1.7.0jdv-rcp-organe-cisisJDV RCP Organe CISIS
ans.fr.terminologies#1.7.0jdv-traitement-soins-frcp-cisisJDV Traitement Soins Frcp CISIS

Resources that this resource uses

No resources found


Narrative

Note: links and images are rebased to the (stated) source

Generated Narrative: CodeSystem ncit-cs

This case-insensitive code system http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl provides a fragment that includes following codes in a Part Of hierarchy:

LvlCodeDisplayDefinition
1C20189 Property or AttributeA distinguishing quality or prominent aspect of a person, object, action, process, or substance.
2  C48191 InformationKnowledge derived from study, experience, or instruction that has been gathered or received by communication.
3    C60776 Contact InformationInformation regarding the means of contacting a person or group.
4      C218693 Designated Medical Expert Contact InformationThe contact information for the sponsor's representative who can advise on specific trial-related medical questions or problems.
2  C25162 CodeA symbol or combination of symbols which is assigned to the members of a collection.
3    C20108 Country CodeAn alphanumeric system designed to identify countries. The ISO 3166 standard includes a two letter representation, a three letter representation, and a 3 number representation. The last two are identical to the UN system. The US State Department system maintains a separate two letter representation code set.
4      C54641 Alpha-2 Country CodeThe two-letter country codes specified by the ISO 3166-1 country code standard.
4      C54642 Alpha-3 Country CodeThe three-letter country codes specified by the ISO 3166-1 country code standard.
4      C54640 Numeric Country CodeThe numeric, three-digit country codes specified by the ISO 3166-1 country code standard.
4      C165131 Study Country Codeno definition found
2  C41009 QualifierA term that helps define and render a concept unique.
3    C21514 Temporal QualifierTerms used to indicate units of time or other terms associated with time.
4      C25164 DateThe particular day, month and year an event has happened or will happen.
5        C71476 Approval DateA date of an official approbation, recognition, or acceptance as satisfactory.
6          C132352 Protocol Approval by Sponsor DateThe date that the sponsor approved a version of the protocol.
5        C93702 Version DateThe date (and time) on which an entity is versioned.
6          C93813 Document Version DateThe date on which the document is versioned.
3    C27993 General QualifierA term that helps define and render another concept unique.
4      C17998 UnknownNot known, observed, recorded; or reported as unknown by the data contributor.
5        C150003 Unknown TransformationIt is unknown whether any transformation of the product takes place.
4      C48655 Missing Value ReasonA specific reason explaining why a meaningful value is not available. A meaningful value answers the question posed by a Data Element Concept. In contrast, a Missing Value Reason answers the implicit question "Why is there no 'meaningful' value?", when there is none.
5        C48660 Not ApplicableDetermination of a value is not relevant in the current context.
4      C17649 OtherDifferent than the one(s) previously specified or mentioned.
4      C68846 GlobalCovering or affecting the whole of a system.
4      C217026 Not GlobalCovering or affecting only a portion of the entire system.
4      C218489 By CohortCovering or affecting a cohort of individuals.
3    C13442 Anatomy QualifierAn adjectival term used to specify a region of the body or other concepts associated with the body.
4      C41065 LocallyTo a restricted area (of the body).
2  C25341 LocationA position, site, or point in space where something can be found.
3    C222063 Location of Medical Expert Contact InformationThe physical or virtual location of the medical expert (as designated by the sponsor) contact information.
3    C218484 Location of Sponsor Approval DateThe physical or virtual location of the date on which the sponsor approved the current version of the protocol.
3    C222064 Location of Sponsor Signatory InformationThe physical or virtual location of the sponsor signatory information.
1C43431 ActivityAn active process; excludes processes and mechanisms which fulfill biological functions.
2  C16326 BehaviorThe actions or reactions of an object or organism, usually in relation to the environment or surrounding world of stimuli.
3    C16452 CommunicationThe exchange of information between objects, people, or groups.
4      C82658 Communication ResponseA statement (either spoken or written) that is made in reply to a question, request, criticism, or accusation.
5        C49149 AnswerA statement (either spoken or written) that is made in reply to a question or request or criticism or accusation; a statement that solves a problem or explains how to solve the problem.
6          C49487 NoThe non-affirmative response to a question.
6          C49488 YesThe affirmative response to a question.
3    C19683 Personal BehaviorThe observable response of a person.
4      C16735 Informed ConsentConsent by a patient to a surgical or medical procedure or participation in a clinical study after achieving an understanding of the relevant medical facts and the risks involved.
2  C16203 Clinical or Research ActivityAny specific activity undertaken during the course of a clinical study or research protocol.
3    C15429 Research ActivitySystematic investigation into a subject in order to discover facts, establish or revise a theory, or develop a plan of action based on the facts discovered.
4      C63536 StudyA detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.
5        C15206 Clinical StudyResearch conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.
6          C208216 Clinical Study by TypeA clinical study classified by its type, such as observational studies, case-control studies, cohort studies, cross-sectional studies, and clinical trials.
7            C71104 Clinical TrialA research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
8              C70820 Clinical Trial by PhaseA description of a clinical trial by the phase of the trial (I, II, III, or IV).
9                C54721 Early Phase 1 TrialExploratory clinical trials, in a small number of participants, that are conducted early in Phase 1. The investigational trial intervention is administered at a low dose for a limited time. Early Phase 1 trials provide insights into a variety of parameters such as pharmacokinetic, pharmacodynamic, and other biomarkers. They involve limited human exposure, have no therapeutic or diagnostic intent, and are not intended to assess clinical tolerability.
9                C15600 Phase I TrialExploratory clinical trials that may be first-in-human, conducted in a small number of patients or healthy volunteers to evaluate clinical safety, tolerability, or therapeutic intent (pharmacokinetics and pharmacodynamics) of an investigational trial intervention.
10                  C142564 First-in-Human StudyA type of phase 1 clinical trial in which the test product is administered to human beings for the first time.
10                  C199990 Phase Ia TrialA type of phase 1 trial with a single ascending dose (dose escalation) in a small group of patients (in comparison to a Phase 1b).
10                  C199989 Phase Ib TrialA type of phase 1 trial with multiple ascending doses (dose expansion) in a larger group of patients (in comparison to a Phase 1a).
9                C15693 Phase I/II TrialA single clinical trial that combines elements of Phase 1 and Phase 2 trials, which may begin as a Phase 1 trial and transition into Phase 2 based upon predetermined criteria.
10                  C15835 Phase I and II Vaccine TrialsSelect candidate vaccines or concepts suitable for Phase I and Phase II trials and conduct these trials.
9                C198366 Phase I/II/III TrialA study that begins as a Phase I study and transitions into Phases II and III based upon successful completion of each previous portion.
9                C198367 Phase I/III TrialA study that begins as a Phase I study and transitions into a Phase III study upon successful completion of the Phase I portion.
9                C15601 Phase II TrialExploratory trials conducted to evaluate the safety and efficacy of the investigational trial intervention in patients with the disease or condition. Objectives may include, but are not limited to, clinical pharmacology, dose-ranging (dose-response, frequency of dosing), type of patients, or other characteristics of safety and efficacy.
10                  C49686 Phase IIa TrialA clinical research protocol generally referred to as a pilot or feasibility trial that aims to prove the concept of the new intervention in question.
10                  C49688 Phase IIb TrialA clinical research protocol generally referred to as a well-controlled and pivotal trial that aims to prove the mechanism of action of the new intervention in question. A pivotal study will generally be well-controlled, randomized, of adequate size, and whenever possible, double-blind.
9                C15694 Phase II/III TrialA type of clinical study that combines elements characteristic of traditional Phase II and Phase III trials.
9                C217024 Phase II/III/IV TrialA study that begins as a Phase II study and transitions into Phases III and IV based upon successful completion of each previous portion.
9                C15602 Phase III TrialConfirmatory trials conducted to demonstrate safety, efficacy and tolerability of the investigational trial intervention in patients with the disease or condition. Their objectives are to evaluate the overall benefit-risk relationship and may provide substantial evidence for regulatory approval and product information.
10                  C15873 Phase III Large Scale Vaccine TrialSelect suitable vaccine candidates and support efficacy trials when appropriate criteria are met.
10                  C49687 Phase IIIa TrialA classification typically assigned retrospectively to a Phase III trial after regulatory authorities determined the need for a Phase III B trial.
10                  C49689 Phase IIIb TrialA type of Phase III trial executed near the time of approval to elicit additional findings. This type of trial may be required as a condition of regulatory authority approval.
9                C217025 Phase III/IV TrialA type of clinical study that combines elements characteristic of traditional Phase III and Phase IV trials.
9                C15603 Phase IV TrialPost-approval (or post-marketing) trials conducted to further evaluate the safety and efficacy of an investigational trial intervention in its approved indication and may be conducted to address a regulatory requirement. These studies may explore use of the investigational trial intervention in the real-world setting of clinical practice and may also inform health economics and health technology assessments.
2  C16847 TechniqueA practiced and regimented skill or series of actions.
3    C20368 Research TechniqueTechnique used in the laboratory for scientific research.
4      C60819 AssayA qualitative or quantitative analysis performed to determine the amount of a particular constituent in a sample or the biological or pharmacological properties or activity of a drug or substance.
5        C15958 In Vitro AssayAssay conducted in an artificial environment, such as in a test tube, under a defined and controlled set of solvent and solute conditions.
6          C17635 Tumor Necrosis Factor AssayAn immunoassay to detect Tumor Necrosis Factor (TNF), which is a potent lymphoid factor, and exerts cytotoxic effects on a wide range of tumor cells and other target cells. Utilizes monoclonal antibody to TNF immobilized on microtitre plate.
1C20181 Conceptual EntityAn organizational header for concepts representing mostly abstract entities.
2  C19160 Occupation or DisciplineA grouping of occupations and fields of study.
3    C25193 OccupationThe principal activity that a person does to earn money.
4      C25392 ManufacturerA person, enterprise, or entity that produces finished goods.
5        C156625 Device ManufactureA person or entity that designs, manufactures, fabricates, assembles, or processes a finished device.
2  C49154 StatementA verbal and/or written message that asserts, affirms, or declares something.
3    C218474 Protocol Amendment Details Statementno definition found
4      C218485 Protocol Not AmendedThis protocol has not been amended.
4      C218488 Protocol Previously Amended See Summary of Changes Before the Table of ContentsThis protocol has been amended previously. The Protocol Amendment Summary of Changes for the current amendment is located directly before the Table of Contents. Prior amendment(s) to this protocol are listed in the table below, beginning with the most recent.
4      C218487 Protocol Previously Amended, Details PresentedThis protocol has been amended previously. Details of prior amendments are presented in Section 12.3 Prior Protocol Amendment(s).
4      C218486 First Protocol AmendmentThis is the first protocol amendment.
2  C25180 IndicatorAn event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.
3    C218673 Amendment Scope Global Applicability IndicatorA descriptive indicator of whether the amendment scope applies globally across the trial.
3    C218672 Original Protocol IndicatorAn indication as to whether the protocol document reflects the original version of the protocol.
2  C25257 PhaseA distinguishable part, a stage in a series of events or in a process of development, e.g. any of the varying aspects or stages in course of a disease; a fraction of a cycle.
3    C48281 Trial PhaseClinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed.
2  C25638 ReasonAn explanation of the cause of some phenomenon or action.
3    C207457 Study Amendment ReasonThe rationale for the change(s) to, or formal clarification of, a protocol.
4      C218497 Change in Standard Of Care Amendment ReasonA change in the standard of care necessitates a change(s) to, or formal clarification of, the protocol.
4      C218496 Change in Strategy Amendment ReasonA change in the study purpose or intent of the scientific plan necessitates a change(s) to, or formal clarification of, the protocol.
4      C218495 IMP Addition Amendment ReasonThe addition of an investigational medicinal product to a clinical trial design necessitates a change(s) to, or formal clarification of, the protocol.
4      C218501 Inconsistency and/or Error in the Protocol Amendment ReasonAn error or inconsistency in the protocol necessitates a change(s) to, or formal clarification of, the protocol.
4      C218499 Investigator/Site Feedback Amendment ReasonFeedback from the investigator or study site necessitates a change(s) to, or formal clarification of, the protocol.
4      C218492 IRB/IEC Feedback Amendment ReasonFeedback from the institutional review board or independent ethics committee necessitates a change(s) to, or formal clarification of, the protocol.
4      C218494 Manufacturing Change Amendment ReasonA change to manufacturing processes of the study agents necessitates a change(s) to, or formal clarification of, the protocol.
4      C218498 New Data Available (Other Than Safety Data) Amendment ReasonPreviously unavailable data (other than safety data) becomes available, which necessitates a change(s) to, or formal clarification of, the protocol.
4      C218491 New Regulatory Guidance Amendment ReasonA regulatory agency has published a guidance document that necessitates a change(s) to, or formal clarification of, the protocol.
4      C218493 New Safety Information Available Amendment ReasonPreviously unavailable safety data becomes available, which necessitates a change(s) to, or formal clarification of, the protocol.
4      C218502 Protocol Design Error Amendment ReasonA protocol design error necessitates a change(s) to, or formal clarification of, a document.
4      C218500 Recruitment Difficulty Amendment ReasonChallenges with participant recruitment necessitates a change(s) to, or formal clarification of, the protocol.
4      C218490 Regulatory Agency Request to Amend Amendment ReasonA regulatory agency has expressed a need for a change(s) to, or formal clarification of, the protocol.
2  C25190 PersonA human being.
3    C198995 Person by OccupationTypeAn individual who is classified by their work type.
4      C17445 CaregiverThe primary person in charge of the care of a patient, usually a family member or a designated health care professional.
5        C53427 Other CaregiverDifferent from the previously specified or mentioned type of person who has primary responsibility for the assistance and supervision for an individual.
3    C198997 Person by Activity TypeA person described by an activity with which they are engaged.
4      C48355 SponsorA person or organization that supports or champions something.
5        C71136 Regulatory Application SponsorThe party who submits a marketing application to FDA for approval of a drug, device, or biologic product. An applicant is the person or entity who assumes responsibility for the marketing of a new medical product, including responsibility for compliance with applicable provisions of the Federal Food, Drug, and Cosmetic Act and related regulations. The sponsor is usually an individual, partnership, corporation, government agency, manufacturer or scientific institution.
5        C142679 Secondary SponsorAdditional individuals, organizations or other legal persons, if any, that have agreed with the primary sponsor to take on sponsorship responsibilities. (WHO)
5        C93478 Study Legal SponsorA sponsor that initiates the investigation and is legally responsible for the study.
5        C215669 Study Co-SponsorAn individual, company, institution, or organization that is designated by the study sponsor as a vested partner in the study.
5        C215670 Local Legal SponsorThe sponsor's legal representative at a geographical region within which the sponsor has no legal presence. (ICH M11)
5        C70793 Clinical Study SponsorAn individual, company, institution, or organization that takes responsibility for the initiation, management, and/or financing of a clinical study. (CDISC Glossary)
6          C187708 Commercial Clinical Trial SponsorA person or organization that takes responsibility for a trial which is part of the development program for a marketing authorization of a medicinal product at the time of the application. (EUDRACT)
6          C187709 Non-commercial Clinical Trial SponsorA person or organization that takes responsibility for a trial that is not part of the development program for a marketing authorization of a medicinal product at the time of the application. (EUDRACT)
6          C70794 Primary Clinical Study SponsorThe individual, organization, group or other legal person taking responsibility for securing the arrangements to initiate and/or manage a study (including arrangements to ensure that the study design meets appropriate standards and to ensure appropriate conduct and reporting). In commercial trials, the primary sponsor is normally the main applicant for regulatory authorization to begin the study. It may or may not be the main funder.
6          C70795 Secondary Clinical Study SponsorAdditional individuals, organizations or other legal persons, if any, that have agreed with the primary sponsor to take on responsibilities of sponsorship. A secondary sponsor may have agreed -to take on all the responsibilities of sponsorship jointly with the primary sponsor; or to form a group with the primary sponsor in which the responsibilities of sponsorship are allocated among the members of the group; or to act as the sponsor's legal representative in relation to some or all of the study sites; or to take responsibility for the accuracy of study registration information submitted.
2  C43359 GroupAny number of entities (members) considered as a unit.
3    C17005 Population GroupA group of individuals united by a common factor (e.g., geographic location, ethnicity, disease, age, sex).
4      C60758 PersonnelPersons employed in any field.
5        C17089 Research PersonnelPeople engaged in research.
6          C51876 Sponsor Medical ExpertA physician or health care provider selected by the sponsor to be readily available to advise clinical trial officials on trial related medical questions or problems.
6          C51824 EvaluatorA person who determines the significance, worth, or condition of something by careful appraisal and study.
7            C207599 Outcomes AssessorThe individual who evaluates the outcome(s) of interest.
6          C25936 InvestigatorAn individual who conducts scientific research. In a clinical setting this individual actually conducts and/or supervises the clinical investigation and study-related procedures. The investigator monitors the safety of the trial subjects and investigational staff (under whose immediate direction an agent is administered or dispensed to a subject). The investigator collects and analyses data and study documents, and provides reports in compliance with applicable requirements.
7            C70722 Investigator by Role in StudyThe characteristic that defines the responsibility of the investigator on a particular study.
8              C51812 Co-InvestigatorOne of two or more scientists working together on a research project. A person that equally contributes to the preparation of the protocol, and shares the responsibilities of this position, including medical monitoring (particularly toxicity/safety), liaison with statisticians over analysis, and the generation of a report containing the results.
8              C51818 Coordinating InvestigatorA research scientist whose task is to see that work, or events, goes harmoniously.
9                C154706 National Coordinating InvestigatorIn the case of a multinational study, a person who has the responsibilities of the sponsor of the study in his/her country and will be responsible for the coordination of the principal investigators at different sites within that member state. (EMA)
8              C51825 Grant InvestigatorAn individual designated by the grantee to take part in the conduction of the study or to participate in a scientific activity being supported by the grant.
8              C19924 Principal InvestigatorAn investigator who is responsible for all aspects of the conduct of a study.
9                C51817 Contract Principal InvestigatorA scientist or health care professional that has a financial agreement, as outlined in a binding statement of work, with the sponsor to bear full and ultimate responsibility for the scientific, administrative, ethical, legal, technical, and fiscal aspects of the study, and for day-to-day management of the scientific project, as well as for documenting and reporting its results.
9                C63403 Funded Principal InvestigatorThe investigator named on the award document. This investigator has full and ultimate responsibility for all research conducted under the award.
9                C51826 Grant Principal InvestigatorAn individual designated by the grantee to direct the project or activity being supported by the grant. He or she is responsible for the scientific, legal, administrative, and technical aspects of the grant and accountable to the grantee for the proper conduct of the project or activity. The Principle Investigator (PI) must have a formal written appointment with the applicant organization, which must be in the form of an official relationship between the parties, but need not involve a salary or other form of remuneration. The PI is a member of the grantee team responsible for ensuring compliance with the financial and administrative aspects of the award and with organizational as well as Federal requirements.
8              C51856 Protocol Lead InvestigatorPrimary clinical researcher of a clinical trial, ultimately responsible for all aspects in the conduct of a study, but has special responsibility with regard to the implementation and administration of the study design, and methodology of a trial.
8              C51875 Site Representative InvestigatorThe investigator who officially represents a clinical site that participates in a multicentral clinical trial. The responsibilities of the official include the management of site compliance with rules and regulations and attention to personnel and patient requisites.
8              C54622 SubinvestigatorAny individual member of the clinical trial team designated and supervised by the investigator at a trial site to perform critical trial-related procedures and/or to make important trial-related decisions (e.g., associates, residents, research fellows).
7            C214478 Non-Physician InvestigatorA researcher who does not have a degree in medicine.
7            C93404 Study Site InvestigatorA researcher at a study site who oversees multiple aspects of the study at a site, including protocol submission for IRB approval, participant recruitment, informed consent, data collection, and analysis.
7            C198656 Treating InvestigatorThe study investigator in charge of administering treatment to study participants.
2  C48910 SubjectSome matter, situation, or event that is thought about, written about, or discussed.
3    C79916 Investigative SubjectAn entity, either biologic or otherwise, of interest in an investigation.
4      C41189 Study SubjectA matter or an individual that is observed, analyzed, examined, investigated, experimented upon, or/and treated in the course of a particular study.
5        C142710 Study ParticipantAny individiual that has a role in a study, including study personnel and study subjects.
6          C188266 High Risk Study ParticipantA participant in a study that presents a greater than moderate risk due to the increased probability for generating serious adverse events. Since there is a probability of an event that is serious and prolonged or permanent occurring as a result of study participation, the participant will require high intensity monitoring.
2  C25198 RecordAnything (e.g., a document) providing permanent evidence of or information about past events.
3    C19498 DocumentA physical object, or electronic counterpart, that is characterized by containing writing which is meant to be human-readable.
4      C42651 ProtocolA rule which guides how an activity should be performed.
5        C70705 Component of Study ProtocolA component of a plan on which a study is based.
6          C181183 Protocol StatementA written message providing an official assurance, account, or assertion within the study protocol.
7            C181236 Protocol Confidentiality StatementA written message within the study protocol that asserts a statement of non-disclosure, such that information contained within the protocol document may only be shared with authorized parties.
4      C25678 SignatureIndividual's name or personal mark, used to sign documents and employed to signify that the writing which precedes accords with one's wishes and intentions; having a handwritten signature.
5        C222014 Sponsor SignatoryA block of text containing the name and signature of the sponsor's signatory, along with the signature date.
4      C25364 IdentifierOne or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.
5        C83081 Study Site IdentifierA sequence of characters used to identify, name, or characterize the study site.
5        C218674 Region IdentifierA sequence of characters used to identify and/or name the region.
5        C218690 Other Regulatory or Clinical Trial IdentifierA sequence of characters assigned by a regulatory agency or other health authority that is used to identify a clinical trial, and that is different than the one(s) previously specified or mentioned.
5        C96095 Product Identifierno definition found
6          C218675 Sponsor's Investigational Product CodeA symbol or combination of symbols that are assigned by the sponsor to uniquely identify an experimental intervention.
5        C70663 Unique IdentifierA set of characters used as a code that is unique in the context or the system for which it is created. It serves as a means of identification and reference (often instead of a name) for an entity, person, thing, function, procedure, activity, variable, or body of data.
6          C98714 Clinical Trial Registry IdentifierA sequence of letters, numbers, or other characters that uniquely identifies a clinical trial within a clinical trial registry.
7            C172240 Clinicaltrials.gov IdentifierThe unique alphanumeric identifier for a trial as assigned by the Clinicaltrials.gov Protocol Registration and Results System (PRS).
8              C127792 Clinicaltrials.gov NCT Number for the Expanded Access RecordThe unique alphanumeric identifier for a study with associated expanded access record, as assigned by the clinicaltrials.gov PRS system.
5        C132299 Protocol IdentifierA sequence of letters, numbers, or other characters that uniquely identifies a study protocol.
6          C132351 Sponsor Protocol IdentifierA unique code, which is assigned by the sponsor, that identifies a specific protocol.
5        C218689 WHO/UTN NumberA sequence of characters used to identify a clinical trial, as assigned by the World Health organization's International Clinical Trial's Registry Platform (ICTRP).
5        C218477 Amendment IdentifierA sequence of characters used to uniquely identify a protocol amendment.
5        C218688 NMPA IND NumberA sequence of characters used to identify a clinical trial under an Investigational New Drug (IND) application, as assigned by the Chinese National Medicinal Products Administration (NMPA).
5        C218686 US FDA Investigational Device Exemption Application NumberA sequence of characters used to identify a clinical trial under an Investigational Device Exemption (IDE) application, as assigned by the US Food and Drug Administration.
5        C218684 EU Clinical Trial Register NumberA sequence of characters used to identify a clinical trial, as assigned by the Clinical Trials Information System (CTIS) of the European Medicines Agency.
5        C218687 Japan Registry for Clinical Trials NumberA sequence of characters used to identify a clinical trial, as assigned by the Japan Registry for Clinical Trials (JRCT) of the Ministry of Health, Labour and Welfare (MHLW) in Japan.
5        C218685 US FDA Investigational New Drug Application NumberA sequence of characters used to identify a clinical trial under an Investigational New Drug (IND) application, as assigned by the US Food and Drug Administration.
4      C25704 TextThe words of something written.
5        C207508 Narrative Content TextA textual representation of the narrative content.
5        C93703 Version Number TextA numeric character string that identifies a form or variant of a type or original.
6          C181232 Study Protocol Version NumberA string of numerals that uniquely identifies a specific version of a study protocol.
4      C25407 AddressA standardized representation of the location of a person, business, building, or organization.
5        C70946 Postal AddressA physical location used by a person or organization for the purpose of receiving postal mail deliveries.
6          C93844 Health Care Provider Postal AddressA contact point used to send physical forms of communication to the healthcare provider.
6          C93847 Healthcare Facility Postal AddressA contact point used to send physical forms of communication to the healthcare facility.
6          C164841 Insured Person Postal Addressno definition found
6          C93875 Organization Postal AddressA contact point used to send physical forms of communication to the organization.
6          C164888 Organization Staff Role Postal Addressno definition found
6          C93880 Organizational Contact Postal AddressA contact point used to send physical forms of communication to the organizational contact.
6          C93983 Performer Postal AddressA contact point used to send physical forms of communication to the performer.
6          C93990 Person Postal AddressA contact point used to send physical forms of communication to the person.
6          C165044 Point Of Contact Postal Addressno definition found
6          C94065 Research Staff Postal AddressA contact point used to send physical forms of communication to the research staff.
6          C95395 Service Delivery Location Postal AddressThe postal address of the service delivery location.
6          C176376 Study Contact Postal AddressA physical location used by a study contact for the purpose of receiving postal mail deliveries.
6          C165133 Study Country Personnel Postal Addressno definition found
6          C94101 Study Personnel Postal AddressA contact point used to send physical forms of communication to the study personnel.
6          C94147 Study Site Personnel Postal AddressA contact point used to send physical forms of communication to the study site personnel.
5        C218677 Sponsor Legal AddressThe legally registered address of the trial sponsor.
5        C218679 Co-Sponsor Legal AddressThe legally registered address of the trial co-sponsor.
5        C218683 Device Manufacturer Legal AddressThe legally registered address of the device manufacturer.
5        C218681 Local Sponsor Legal AddressThe legally registered address of the sponsor's legal representative at a geographical region within which the sponsor has no legal presence.
2  C25480 DetailsParticulars considered individually and in relation to a whole.
3    C218694 Protocol Amendment DetailsParticulars about the protocol amendment, considered individually and in relation to a whole.
2  C42614 NameThe words or language units by which a thing is known.
3    C218678 Co-Sponsor NameThe literal identifier (i.e., distinctive designation) of the trial co-sponsor.
3    C218682 Device Manufacturer NameThe literal identifier (i.e., distinctive designation) of the organization defined as being responsible for creating the device as stated on the package in which the product is supplied.
3    C218680 Local Sponsor NameThe literal identifier (i.e., distinctive designation) of the sponsor's legal representative at a geographical region within which the sponsor has no legal presence.
3    C222495 Trial Sponsor NameThe literal identifier (i.e., distinctive designation) of the trial sponsor.
3    C42774 TitleAn official descriptive name of a document, e.g. the long name of a study protocol provided by the study sponsor.
4      C132300 Protocol TitleThe name of a study protocol.
5        C132346 Official Protocol TitleThe formal, descriptive name of the protocol.
4      C93637 Public TitleThe title of the document intended for the general population.
5        C94105 Study Protocol Document Version Public TitleThe short descriptive name for the trial.
4      C49802 Trial TitleThe name of a clinical trial.
5        C207615 Brief Study TitleThe short descriptive name for the study.
5        C207618 Scientific Study TitleA more extensive descriptive name of the study that is intended for medical professionals, written using medical and scientific language.
5        C207616 Official Study TitleThe formal descriptive name for the study.
5        C207617 Public Study TitleThe descriptive name of the study that is intended for the lay public, written in easily understood language.
3    C93495 AcronymThe non-unique initials or abbreviated name used for identification.
4      C94108 Study Protocol Version AcronymThe non-unique initials or abbreviated name used for identification of the study protocol document version.
4      C207646 Study AcronymThe non-unique initials or abbreviated name used for identification of the study.
3    C71898 Proprietary NameThe part of the name or logo associated with a specific product or service identifying and distinguishing it from varieties of the same product or service marketed by competing companies.
3    C97054 Generic NameDrug name that is not protected by a trademark, usually descriptive of its chemical structure, and sometimes a public name.
4      C202465 Compendial NameA name within a pharmaceutical compendium that designates a small or large molecule substance that complies with compendial standards for strength, quality, and purity. (USP Nomenclature Guidelines)
4      C142585 International Nonproprietary NameA unique, internationally consistent and globally recognized name which identifies pharmaceutical substances or active pharmaceutical ingredients and is public property.
4      C96973 United States Adopted NameA unique nonproprietary name assigned to drugs and biologics by the United States Adopted Names Council (USAN).
4      C203358 USP-NF Established NameA unique nonproprietary name assigned to drugs and biologics by the United States Pharmacopeia (USP) or excipients by the National Formulary (NF).
2  C19067 TitleAn identifying designation.
3    C215610 Document Content Reference Section TitleAn identifying designation for a particular section for the document content reference.
4      C217359 Protocol Section TitleAn identifying designation for a section within a protocol document.
5        C217360 ICH M11 Protocol Section TitleAn identifying designation for a section within the ICH M11 protocol template document.
6          C218514 ICH M11 Protocol Section 1 PROTOCOL SUMMARYThe title of section 1 of the ICH M11 protocol guideline: PROTOCOL SUMMARY.
6          C218515 ICH M11 Protocol Section 1.1 Protocol SynopsisThe title of section 1.1 of the ICH M11 protocol guideline: Protocol Synopsis.
6          C218516 ICH M11 Protocol Section 1.1.1 Primary and Secondary Objectives and EstimandsThe title of section 1.1.1 of the ICH M11 protocol guideline: Primary and Secondary Objectives and Estimands.
6          C218517 ICH M11 Protocol Section 1.1.2 Overall DesignThe title of section 1.1.2 of the ICH M11 protocol guideline: Overall Design.
6          C218518 ICH M11 Protocol Section 1.2 Trial SchemaThe title of section 1.2 of the ICH M11 protocol guideline: Trial Schema.
6          C218519 ICH M11 Protocol Section 1.3 Schedule of ActivitiesThe title of section 1.3 of the ICH M11 protocol guideline: Schedule of Activities.
6          C218625 ICH M11 Protocol Section 10 STATISTICAL CONSIDERATIONSThe title of section 10 of the ICH M11 protocol guideline: STATISTICAL CONSIDERATIONS.
6          C218626 ICH M11 Protocol Section 10.1 General ConsiderationsThe title of section 10.1 of the ICH M11 protocol guideline: General Considerations.
6          C218647 ICH M11 Protocol Section 10.10 Multiplicity AdjustmentsThe title of section 10.10 of the ICH M11 protocol guideline: Multiplicity Adjustments.
6          C218648 ICH M11 Protocol Section 10.11 Sample Size DeterminationThe title of section 10.11 of the ICH M11 protocol guideline: Sample Size Determination.
6          C218627 ICH M11 Protocol Section 10.2 Analysis SetsThe title of section 10.2 of the ICH M11 protocol guideline: Analysis Sets.
6          C218628 ICH M11 Protocol Section 10.3 Analyses of Demographics and Other Baseline VariablesThe title of section 10.3 of the ICH M11 protocol guideline: Analyses of Demographics and Other Baseline Variables.
6          C218629 ICH M11 Protocol Section 10.4 Analyses Associated with the Primary Objective(s)The title of section 10.4 of the ICH M11 protocol guideline: Analyses Associated with the Primary Objective(s).
6          C218630 ICH M11 Protocol Section 10.4.1 Primary ObjectiveThe title of section 10.4.1 of the ICH M11 protocol guideline: Primary Objective.
6          C218631 ICH M11 Protocol Section 10.4.1.1 Statistical Analysis MethodThe title of section 10.4.1.1 of the ICH M11 protocol guideline: Statistical Analysis Method.
6          C218632 ICH M11 Protocol Section 10.4.1.2 Handling of Data in Relation to Primary Estimand(s)The title of section 10.4.1.2 of the ICH M11 protocol guideline: Handling of Data in Relation to Primary Estimand(s).
6          C218633 ICH M11 Protocol Section 10.4.1.3 Handling of Missing Data in Relation to Primary Estimand(s)The title of section 10.4.1.3 of the ICH M11 protocol guideline: Handling of Missing Data in Relation to Primary Estimand(s)
6          C218634 ICH M11 Protocol Section 10.4.1.4 Sensitivity AnalysisThe title of section 10.4.1.4 of the ICH M11 protocol guideline: Sensitivity Analysis.
6          C218635 ICH M11 Protocol Section 10.4.1.5 Supplementary AnalysisThe title of section 10.4.1.5 of the ICH M11 protocol guideline: Supplementary Analysis.
6          C218636 ICH M11 Protocol Section 10.5 Analyses Associated with the Secondary Objective(s)The title of section 10.5 of the ICH M11 protocol guideline: Analyses Associated with the Secondary Objective(s).
6          C218637 ICH M11 Protocol Section 10.5.1 Secondary ObjectiveThe title of section 10.5.1 of the ICH M11 protocol guideline: Secondary Objective.
6          C218638 ICH M11 Protocol Section 10.5.1.1 Statistical Analysis MethodThe title of section 10.5.1.1 of the ICH M11 protocol guideline: Statistical Analysis Method.
6          C218639 ICH M11 Protocol Section 10.5.1.2 Handling of Data in Relation to Secondary Estimand(s)The title of section 10.5.1.2 of the ICH M11 protocol guideline: Handling of Data in Relation to Secondary Estimand(s).
6          C218640 ICH M11 Protocol Section 10.5.1.3 Handling of Missing Data in Relation to Secondary Estimand(s)The title of section 10.5.1.3 of the ICH M11 protocol guideline: Handling of Missing Data in Relation to Secondary Estimand(s).
6          C218641 ICH M11 Protocol Section 10.5.1.4 Sensitivity AnalysisThe title of section 10.5.1.4 of the ICH M11 protocol guideline: Sensitivity Analysis.
6          C218642 ICH M11 Protocol Section 10.5.1.5 Supplementary AnalysisThe title of section 10.5.1.5 of the ICH M11 protocol guideline: Supplementary Analysis.
6          C218643 ICH M11 Protocol Section 10.6 Analyses Associated with the Exploratory Objective(s)The title of section 10.6 of the ICH M11 protocol guideline: Analyses Associated with the Exploratory Objective(s).
6          C218644 ICH M11 Protocol Section 10.7 Safety AnalysesThe title of section 10.7 of the ICH M11 protocol guideline: Safety Analyses.
6          C218645 ICH M11 Protocol Section 10.8 Other AnalysesThe title of section 10.8 of the ICH M11 protocol guideline: Other Analyses.
6          C218646 ICH M11 Protocol Section 10.9 Interim AnalysesThe title of section 10.9 of the ICH M11 protocol guideline: Interim Analyses.
6          C218649 ICH M11 Protocol Section 11 TRIAL OVERSIGHT AND OTHER GENERAL CONSIDERATIONSThe title of section 11 of the ICH M11 protocol guideline: TRIAL OVERSIGHT AND OTHER GENERAL CONSIDERATIONS.
6          C218650 ICH M11 Protocol Section 11.1 Regulatory and Ethical ConsiderationsThe title of section 11.1 of the ICH M11 protocol guideline: Regulatory and Ethical Considerations.
6          C218663 ICH M11 Protocol Section 11.10 Protocol DeviationsThe title of section 11.10 of the ICH M11 protocol guideline: Protocol Deviations.
6          C218664 ICH M11 Protocol Section 11.11 Early Site ClosureThe title of section 11.11 of the ICH M11 protocol guideline: Early Site Closure.
6          C218665 ICH M11 Protocol Section 11.12 Data DisseminationThe title of section 11.12 of the ICH M11 protocol guideline: Data Dissemination.
6          C218651 ICH M11 Protocol Section 11.2 Trial OversightThe title of section 11.2 of the ICH M11 protocol guideline: Trial Oversight.
6          C218652 ICH M11 Protocol Section 11.2.1 Investigator ResponsibilitiesThe title of section 11.2.1 of the ICH M11 protocol guideline: Investigator Responsibilities.
6          C218653 ICH M11 Protocol Section 11.2.2 Sponsor ResponsibilitiesThe title of section 11.2.2 of the ICH M11 protocol guideline: Sponsor Responsibilities.
6          C218654 ICH M11 Protocol Section 11.3 Informed Consent ProcessThe title of section 11.3 of the ICH M11 protocol guideline: Informed Consent Process.
6          C218655 ICH M11 Protocol Section 11.3.1 Informed Consent for RescreeningThe title of section 11.3.1 of the ICH M11 protocol guideline: Informed Consent for Rescreening.
6          C218656 ICH M11 Protocol Section 11.3.2 Informed Consent for Use of Remaining Samples in Exploratory ResearchThe title of section 11.3.2 of the ICH M11 protocol guideline: Informed Consent for Use of Remaining Samples in Exploratory Research.
6          C218657 ICH M11 Protocol Section 11.4 CommitteesThe title of section 11.4 of the ICH M11 protocol guideline: Committees.
6          C218658 ICH M11 Protocol Section 11.5 Insurance and IndemnityThe title of section 11.5 of the ICH M11 protocol guideline: Insurance and Indemnity.
6          C218659 ICH M11 Protocol Section 11.6 Risk-Based Quality ManagementThe title of section 11.6 of the ICH M11 protocol guideline: Risk-Based Quality Management.
6          C218660 ICH M11 Protocol Section 11.7 Data GovernanceThe title of section 11.7 of the ICH M11 protocol guideline: Data Governance.
6          C218661 ICH M11 Protocol Section 11.8 Data ProtectionThe title of section 11.8 of the ICH M11 protocol guideline: Data Protection.
6          C218662 ICH M11 Protocol Section 11.9 Source RecordsThe title of section 11.9 of the ICH M11 protocol guideline: Source Records.
6          C218666 ICH M11 Protocol Section 12 APPENDIX: SUPPORTING DETAILSThe title of section 12 of the ICH M11 protocol guideline: APPENDIX: SUPPORTING DETAILS.
6          C218667 ICH M11 Protocol Section 12.1 Clinical Laboratory TestsThe title of section 12.1 of the ICH M11 protocol guideline: Clinical Laboratory Tests.
6          C218668 ICH M11 Protocol Section 12.2 Country/Region-Specific DifferencesThe title of section 12.2 of the ICH M11 protocol guideline: Country/Region-Specific Differences.
6          C218669 ICH M11 Protocol Section 12.3 Prior Protocol Amendment(s)The title of section 12.3 of the ICH M11 protocol guideline: Prior Protocol Amendment(s).
6          C218670 ICH M11 Protocol Section 13 APPENDIX: GLOSSARY OF TERMS AND ABBREVIATIONSThe title of section 13 of the ICH M11 protocol guideline: APPENDIX: GLOSSARY OF TERMS AND ABBREVIATIONS.
6          C218671 ICH M11 Protocol Section 14 APPENDIX: REFERENCESThe title of section 14 of the ICH M11 protocol guideline: APPENDIX: REFERENCES.
6          C218520 ICH M11 Protocol Section 2 INTRODUCTIONThe title of section 2 of the ICH M11 protocol guideline: INTRODUCTION.
6          C218521 ICH M11 Protocol Section 2.1 Purpose of TrialThe title of section 2.1 of the ICH M11 protocol guideline: Purpose of Trial.
6          C218522 ICH M11 Protocol Section 2.2 Assessment of Risks and BenefitsThe title of section 2.2 of the ICH M11 protocol guideline: Assessment of Risks and Benefits.
6          C218523 ICH M11 Protocol Section 2.2.1 Risk Summary and Mitigation StrategyThe title of section 2.2.2 of the ICH M11 protocol guideline: Risk Summary and Mitigation Strategy.
6          C218524 ICH M11 Protocol Section 2.2.2 Benefit SummaryThe title of section 2.2.1 of the ICH M11 protocol guideline: Benefit Summary.
6          C218525 ICH M11 Protocol Section 2.2.3 Overall Risk-Benefit AssessmentThe title of section 2.2.3 of the ICH M11 protocol guideline: Overall Risk-Benefit Assessment.
6          C218526 ICH M11 Protocol Section 3 TRIAL OBJECTIVES AND ASSOCIATED ESTIMANDSThe title of section 3 of the ICH M11 protocol guideline: TRIAL OBJECTIVES AND ASSOCIATED ESTIMANDS.
6          C218527 ICH M11 Protocol Section 3.1 Primary Objective(s) and Associated Estimand(s)The title of section 3.1 of the ICH M11 protocol guideline: Primary Objective(s) and Associated Estimand(s).
6          C218528 ICH M11 Protocol Section 3.1.1 Primary ObjectiveThe title of section 3.1.1 of the ICH M11 protocol guideline: Primary Objective.
6          C218529 ICH M11 Protocol Section 3.2 Secondary Objective(s) and Associated Estimand(s)The title of section 3.2 of the ICH M11 protocol guideline: Secondary Objective(s) and Associated Estimand(s).
6          C218530 ICH M11 Protocol Section 3.2.1 Secondary ObjectiveThe title of section 3.2.1 of the ICH M11 protocol guideline: Secondary Objective.
6          C218531 ICH M11 Protocol Section 3.3 Exploratory Objective(s)The title of section 3.3 of the ICH M11 protocol guideline: Exploratory Objective(s).
6          C218532 ICH M11 Protocol Section 3.3.1 Exploratory ObjectiveThe title of section 3.3.1 of the ICH M11 protocol guideline: Exploratory Objective.
6          C218533 ICH M11 Protocol Section 4 TRIAL DESIGNThe title of section 4 of the ICH M11 protocol guideline: TRIAL DESIGN.
6          C218534 ICH M11 Protocol Section 4.1 Description of Trial DesignThe title of section 4.1 of the ICH M11 protocol guideline: Description of Trial Design.
6          C218535 ICH M11 Protocol Section 4.1.1 Stakeholder Input into DesignThe title of section 4.1.1 of the ICH M11 protocol guideline: Stakeholder Input into Design.
6          C218536 ICH M11 Protocol Section 4.2 Rationale for Trial DesignThe title of section 4.2 of the ICH M11 protocol guideline: Rationale for Trial Design.
6          C218537 ICH M11 Protocol Section 4.2.1 Rationale for Estimand(s)The title of section 4.2.1 of the ICH M11 protocol guideline: Rationale for Estimand(s).
6          C218538 ICH M11 Protocol Section 4.2.2 Rationale for Intervention ModelThe title of section 4.2.2 of the ICH M11 protocol guideline: Rationale for Intervention Model.
6          C218539 ICH M11 Protocol Section 4.2.3 Rationale for Control TypeThe title of section 4.2.3 of the ICH M11 protocol guideline: Rationale for Control Type.
6          C218540 ICH M11 Protocol Section 4.2.4 Rationale for Trial DurationThe title of section 4.2.4 of the ICH M11 protocol guideline: Rationale for Trial Duration.
6          C218541 ICH M11 Protocol Section 4.2.5 Rationale for Adaptive or Novel Trial DesignThe title of section 4.2.5 of the ICH M11 protocol guideline: Rationale for Adaptive or Novel Trial Design.
6          C218542 ICH M11 Protocol Section 4.2.6 Rationale for Interim AnalysisThe title of section 4.2.6 of the ICH M11 protocol guideline: Rationale for Interim Analysis.
6          C218543 ICH M11 Protocol Section 4.2.7 Rationale for Other Trial Design AspectsThe title of section 4.2.7 of the ICH M11 protocol guideline: Rationale for Other Trial Design Aspects.
6          C218544 ICH M11 Protocol Section 4.3 Trial Stopping RulesThe title of section 4.3 of the ICH M11 protocol guideline: Trial Stopping Rules.
6          C218545 ICH M11 Protocol Section 4.4 Start of Trial and End of TrialThe title of section 4.4 of the ICH M11 protocol guideline: Start of Trial and End of Trial.
6          C218546 ICH M11 Protocol Section 4.5 Access to Trial Intervention After End of TrialThe title of section 4.5 of the ICH M11 protocol guideline: Access to Trial Intervention After End of Trial.
6          C218547 ICH M11 Protocol Section 5 TRIAL POPULATIONThe title of section 5 of the ICH M11 protocol guideline: TRIAL POPULATION.
6          C218548 ICH M11 Protocol Section 5.1 Description of Trial Population and RationaleThe title of section 5.1 of the ICH M11 protocol guideline: Description of Trial Population and Rationale.
6          C218549 ICH M11 Protocol Section 5.2 Inclusion CriteriaThe title of section 5.2 of the ICH M11 protocol guideline: Inclusion Criteria.
6          C218550 ICH M11 Protocol Section 5.3 Exclusion CriteriaThe title of section 5.3 of the ICH M11 protocol guideline: Exclusion Criteria.
6          C218551 ICH M11 Protocol Section 5.4 ContraceptionThe title of section 5.4 of the ICH M11 protocol guideline: Contraception.
6          C218552 ICH M11 Protocol Section 5.4.1 Definitions Related to Childbearing PotentialThe title of section 5.4.1 of the ICH M11 protocol guideline: Definitions Related to Childbearing Potential.
6          C218553 ICH M11 Protocol Section 5.4.2 Contraception RequirementsThe title of section 5.4.2 of the ICH M11 protocol guideline: Contraception Requirements.
6          C218554 ICH M11 Protocol Section 5.5 Lifestyle RestrictionsThe title of section 5.5 of the ICH M11 protocol guideline: Lifestyle Restrictions.
6          C218555 ICH M11 Protocol Section 5.5.1 Meals and Dietary RestrictionsThe title of section 5.5.1 of the ICH M11 protocol guideline: Meals and Dietary Restrictions.
6          C218556 ICH M11 Protocol Section 5.5.2 Caffeine, Alcohol, Tobacco, and Other RestrictionsThe title of section 5.5.2 of the ICH M11 protocol guideline: Caffeine, Alcohol, Tobacco, and Other Restrictions.
6          C218557 ICH M11 Protocol Section 5.5.3 Physical Activity RestrictionsThe title of section 5.5.3 of the ICH M11 protocol guideline: Physical Activity Restrictions.
6          C218558 ICH M11 Protocol Section 5.5.4 Other Activity RestrictionsThe title of section 5.5.4 of the ICH M11 protocol guideline: Other Activity Restrictions.
6          C218559 ICH M11 Protocol Section 5.6 Screen Failure and RescreeningThe title of section 5.6 of the ICH M11 protocol guideline: Screen Failure and Rescreening.
6          C218560 ICH M11 Protocol Section 6 TRIAL INTERVENTION AND CONCOMITANT THERAPYThe title of section 6 of the ICH M11 protocol guideline: TRIAL INTERVENTION AND CONCOMITANT THERAPY.
6          C218561 ICH M11 Protocol Section 6.1 Description of Investigational Trial InterventionThe title of section 6.1 of the ICH M11 protocol guideline: Description of Investigational Trial Intervention.
6          C218580 ICH M11 Protocol Section 6.10 Concomitant TherapyThe title of section 6.10 of the ICH M11 protocol guideline: Concomitant Therapy.
6          C218581 ICH M11 Protocol Section 6.10.1 Prohibited Concomitant TherapyThe title of section 6.10.1 of the ICH M11 protocol guideline: Prohibited Concomitant Therapy.
6          C218582 ICH M11 Protocol Section 6.10.2 Permitted Concomitant TherapyThe title of section 6.10.2 of the ICH M11 protocol guideline: Permitted Concomitant Therapy.
6          C218562 ICH M11 Protocol Section 6.2 Rationale for Investigational Trial Intervention Dose and RegimenThe title of section 6.2 of the ICH M11 protocol guideline: Rationale for Investigational Trial Intervention Dose and Regimen.
6          C218563 ICH M11 Protocol Section 6.3 Investigational Trial Intervention AdministrationThe title of section 6.3 of the ICH M11 protocol guideline: Investigational Trial Intervention Administration.
6          C218564 ICH M11 Protocol Section 6.4 Investigational Trial Intervention Dose ModificationThe title of section 6.4 of the ICH M11 protocol guideline: Investigational Trial Intervention Dose Modification.
6          C218565 ICH M11 Protocol Section 6.5 Management of Investigational Trial Intervention OverdoseThe title of section 6.5 of the ICH M11 protocol guideline: Management of Investigational Trial Intervention Overdose.
6          C218566 ICH M11 Protocol Section 6.6 Preparation, Storage, Handling and Accountability of Investigational Trial InterventionThe title of section 6.6 of the ICH M11 protocol guideline: Preparation, Storage, Handling and Accountability of Investigational Trial Intervention.
6          C218567 ICH M11 Protocol Section 6.6.1 Preparation of Investigational Trial InterventionThe title of section 6.6.1 of the ICH M11 protocol guideline: Preparation of Investigational Trial Intervention.
6          C218568 ICH M11 Protocol Section 6.6.2 Storage and Handling of Investigational Trial InterventionThe title of section 6.6.2 of the ICH M11 protocol guideline: Storage and Handling of Investigational Trial Intervention.
6          C218569 ICH M11 Protocol Section 6.6.3 Accountability of Investigational Trial InterventionThe title of section 6.6.3 of the ICH M11 protocol guideline: Accountability of Investigational Trial Intervention.
6          C218570 ICH M11 Protocol Section 6.7 Investigational Trial Intervention Assignment, Randomisation and BlindingThe title of section 6.7 of the ICH M11 protocol guideline: Investigational Trial Intervention Assignment, Randomisation and Blinding.
6          C218571 ICH M11 Protocol Section 6.7.1 Participant Assignment to Investigational Trial InterventionThe title of section 6.7.1 of the ICH M11 protocol guideline: Participant Assignment to Investigational Trial Intervention.
6          C218572 ICH M11 Protocol Section 6.7.2 RandomisationThe title of section 6.7.2 of the ICH M11 protocol guideline: Randomisation.
6          C218573 ICH M11 Protocol Section 6.7.3 Measures to Maintain BlindingThe title of section 6.7.3 of the ICH M11 protocol guideline: Measures to Maintain Blinding.
6          C218574 ICH M11 Protocol Section 6.7.4 Emergency Unblinding at the SiteThe title of section 6.7.4 of the ICH M11 protocol guideline: Emergency Unblinding at the Site.
6          C218575 ICH M11 Protocol Section 6.8 Investigational Trial Intervention AdherenceThe title of section 6.8 of the ICH M11 protocol guideline: Investigational Trial Intervention Adherence.
6          C218576 ICH M11 Protocol Section 6.9 Description of Noninvestigational Trial InterventionThe title of section 6.9 of the ICH M11 protocol guideline: Description of Noninvestigational Trial Intervention.
6          C218577 ICH M11 Protocol Section 6.9.1 Background Trial InterventionThe title of section 6.9.1 of the ICH M11 protocol guideline: Background Trial Intervention.
6          C218578 ICH M11 Protocol Section 6.9.2 Rescue TherapyThe title of section 6.9.2 of the ICH M11 protocol guideline: Rescue Therapy.
6          C218579 ICH M11 Protocol Section 6.9.3 Other Noninvestigational Trial InterventionThe title of section 6.9.3 of the ICH M11 protocol guideline: Other Noninvestigational Trial Intervention.
6          C218583 ICH M11 Protocol Section 7 PARTICIPANT DISCONTINUATION OF TRIAL INTERVENTION AND DISCONTINUATION OR WITHDRAWAL FROM TRIALThe title of section 7 of the ICH M11 protocol guideline: PARTICIPANT DISCONTINUATION OF TRIAL INTERVENTION AND DISCONTINUATION OR WITHDRAWAL FROM TRIAL.
6          C218584 ICH M11 Protocol Section 7.1 Discontinuation of Trial Intervention for Individual ParticipantsThe title of section 7.1 of the ICH M11 protocol guideline: Discontinuation of Trial Intervention for Individual Participants.
6          C218585 ICH M11 Protocol Section 7.1.1 Permanent Discontinuation of Trial InterventionThe title of section 7.1.1 of the ICH M11 protocol guideline: Permanent Discontinuation of Trial Intervention.
6          C218586 ICH M11 Protocol Section 7.1.2 Temporary Discontinuation of Trial InterventionThe title of section 7.1.2 of the ICH M11 protocol guideline: Temporary Discontinuation of Trial Intervention.
6          C218587 ICH M11 Protocol Section 7.1.3 RechallengeThe title of section 7.1.3 of the ICH M11 protocol guideline: Rechallenge.
6          C218588 ICH M11 Protocol Section 7.2 Participant Discontinuation or Withdrawal from the TrialThe title of section 7.2 of the ICH M11 protocol guideline: Participant Discontinuation or Withdrawal from the Trial.
6          C218589 ICH M11 Protocol Section 7.3 Management of Loss to Follow-UpThe title of section 7.3 of the ICH M11 protocol guideline: Management of Loss to Follow-Up.
6          C218590 ICH M11 Protocol Section 8 TRIAL ASSESSMENTS AND PROCEDURESThe title of section 8 of the ICH M11 protocol guideline: TRIAL ASSESSMENTS AND PROCEDURES.
6          C218591 ICH M11 Protocol Section 8.1 Trial Assessments and Procedures ConsiderationsThe title of section 8.1 of the ICH M11 protocol guideline: Trial Assessments and Procedures Considerations.
6          C218592 ICH M11 Protocol Section 8.2 Screening/Baseline Assessments and ProceduresThe title of section 8.2 of the ICH M11 protocol guideline: Screening/Baseline Assessments and Procedures.
6          C218593 ICH M11 Protocol Section 8.3 Efficacy Assessments and ProceduresThe title of section 8.3 of the ICH M11 protocol guideline: Efficacy Assessments and Procedures.
6          C218594 ICH M11 Protocol Section 8.4 Safety Assessments and ProceduresThe title of section 8.4 of the ICH M11 protocol guideline: Safety Assessments and Procedures.
6          C218595 ICH M11 Protocol Section 8.4.1 Physical ExaminationThe title of section 8.4.1 of the ICH M11 protocol guideline: Physical Examination.
6          C218596 ICH M11 Protocol Section 8.4.2 Vital SignsThe title of section 8.4.2 of the ICH M11 protocol guideline: Vital Signs.
6          C218597 ICH M11 Protocol Section 8.4.3 ElectrocardiogramsThe title of section 8.4.3 of the ICH M11 protocol guideline: Electrocardiograms.
6          C218598 ICH M11 Protocol Section 8.4.4 Clinical Laboratory AssessmentsThe title of section 8.4.4 of the ICH M11 protocol guideline: Clinical Laboratory Assessments.
6          C218599 ICH M11 Protocol Section 8.4.5 Pregnancy TestingThe title of section 8.4.5 of the ICH M11 protocol guideline: Pregnancy Testing.
6          C218600 ICH M11 Protocol Section 8.4.6 Suicidal Ideation and Behaviour Risk MonitoringThe title of section 8.4.6 of the ICH M11 protocol guideline: Suicidal Ideation and Behaviour Risk Monitoring.
6          C218601 ICH M11 Protocol Section 8.5 PharmacokineticsThe title of section 8.5 of the ICH M11 protocol guideline: Pharmacokinetics.
6          C218602 ICH M11 Protocol Section 8.6 BiomarkersThe title of section 8.6 of the ICH M11 protocol guideline: Biomarkers.
6          C218603 ICH M11 Protocol Section 8.6.1 Genetics, Genomics, Pharmacogenetics and PharmacogenomicsThe title of section 8.6.1 of the ICH M11 protocol guideline: Genetics, Genomics, Pharmacogenetics and Pharmacogenomics.
6          C218604 ICH M11 Protocol Section 8.6.2 Pharmacodynamic BiomarkersThe title of section 8.6.2 of the ICH M11 protocol guideline: Pharmacodynamic Biomarkers.
6          C218605 ICH M11 Protocol Section 8.6.3 Other BiomarkersThe title of section 8.6.3 of the ICH M11 protocol guideline: Other Biomarkers.
6          C218606 ICH M11 Protocol Section 8.7 Immunogenicity AssessmentsThe title of section 8.7 of the ICH M11 protocol guideline: Immunogenicity Assessments.
6          C218607 ICH M11 Protocol Section 8.8 Medical Resource Utilisation and Health EconomicsThe title of section 8.8 of the ICH M11 protocol guideline: Medical Resource Utilisation and Health Economics.
6          C218608 ICH M11 Protocol Section 9 ADVERSE EVENTS, SERIOUS ADVERSE EVENTS, PRODUCT COMPLAINTS, PREGNANCY AND POSTPARTUM INFORMATION, AND SPECIAL SAFETY SITUATIONSThe title of section 9 of the ICH M11 protocol guideline: ADVERSE EVENTS, SERIOUS ADVERSE EVENTS, PRODUCT COMPLAINTS, PREGNANCY AND POSTPARTUM INFORMATION, AND SPECIAL SAFETY SITUATIONS.
6          C218609 ICH M11 Protocol Section 9.1 DefinitionsThe title of section 9.1 of the ICH M11 protocol guideline: Definitions.
6          C218610 ICH M11 Protocol Section 9.1.1 Definitions of Adverse EventsThe title of section 9.1.1 of the ICH M11 protocol guideline: Definitions of Adverse Events.
6          C218611 ICH M11 Protocol Section 9.1.2 Definitions of Serious Adverse EventsThe title of section 9.1.2 of the ICH M11 protocol guideline: Definitions of Serious Adverse Events.
6          C218612 ICH M11 Protocol Section 9.1.3 Definitions of Product ComplaintsThe title of section 9.1.3 of the ICH M11 protocol guideline: Definitions of Product Complaints.
6          C218613 ICH M11 Protocol Section 9.1.3.1 Definitions of Medical Device Product ComplaintsThe title of section 9.1.3.1 of the ICH M11 protocol guideline: Definitions of Medical Device Product Complaints.
6          C218614 ICH M11 Protocol Section 9.2 Timing and Procedures for Collection and ReportingThe title of section 9.2 of the ICH M11 protocol guideline: Timing and Procedures for Collection and Reporting.
6          C218615 ICH M11 Protocol Section 9.2.1 TimingThe title of section 9.2.1 of the ICH M11 protocol guideline: Timing.
6          C218616 ICH M11 Protocol Section 9.2.2 Collection ProceduresThe title of section 9.2.2 of the ICH M11 protocol guideline: Collection Procedures.
6          C218617 ICH M11 Protocol Section 9.2.3 ReportingThe title of section 9.2.3 of the ICH M11 protocol guideline: Reporting.
6          C218618 ICH M11 Protocol Section 9.2.3.1 Regulatory Reporting RequirementsThe title of section 9.2.3.1 of the ICH M11 protocol guideline: Regulatory Reporting Requirements.
6          C218619 ICH M11 Protocol Section 9.2.4 Adverse Events of Special InterestThe title of section 9.2.4 of the ICH M11 protocol guideline: Adverse Events of Special Interest.
6          C218620 ICH M11 Protocol Section 9.2.5 Disease-related Events or Outcomes Not Qualifying as AEs or SAEsThe title of section 9.2.5 of the ICH M11 protocol guideline: Disease-related Events or Outcomes Not Qualifying as AEs or SAEs.
6          C218621 ICH M11 Protocol Section 9.3 Pregnancy and Postpartum InformationThe title of section 9.3 of the ICH M11 protocol guideline: Pregnancy and Postpartum Information.
6          C218622 ICH M11 Protocol Section 9.3.1 Participants Who Become Pregnant During the TrialThe title of section 9.3.1 of the ICH M11 protocol guideline: Participants Who Become Pregnant During the Trial.
6          C218623 ICH M11 Protocol Section 9.3.2 Participants Whose Partners Become Pregnant During the TrialThe title of section 9.3.2 of the ICH M11 protocol guideline: Participants Whose Partners Become Pregnant During the Trial.
6          C218624 ICH M11 Protocol Section 9.4 Special Safety SituationsThe title of section 9.4 of the ICH M11 protocol guideline: Special Safety Situations.
6          C222770 ICH M11 Protocol Section Amendment DetailsThe title of the amendment details section of the ICH M11 protocol guideline: Amendment Details.
6          C222769 ICH M11 Protocol Section Title PageTitle Page Section of the ICH M11 Protocol standard, Title Page.

Source1

{
  "resourceType": "CodeSystem",
  "id": "ncit-cs",
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm",
      "valueInteger": 2
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg",
      "valueCode": "brr"
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status",
      "valueCode": "trial-use",
      "_valueCode": {
        "extension": [
          {
            "url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-conformance-derivedFrom",
            "valueCanonical": "http://hl7.org/fhir/uv/clinical-study-protocol/ImplementationGuide/hl7.fhir.uv.clinical-study-protocol"
          }
        ]
      }
    }
  ],
  "url": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
  "version": "1.0.0-ballot2",
  "name": "NCIT",
  "title": "Fragment of NCIT Code System",
  "status": "active",
  "experimental": false,
  "date": "2026-03-30T16:32:09+00:00",
  "publisher": "HL7 International / Biomedical Research and Regulation",
  "contact": [
    {
      "name": "HL7 International / Biomedical Research and Regulation",
      "telecom": [
        {
          "system": "url",
          "value": "http://www.hl7.org/Special/committees/rcrim"
        },
        {
          "system": "email",
          "value": "UDP@HL7Vulcan.org"
        }
      ]
    }
  ],
  "description": "This is a fragment from the NCI Thesaurus covering codes used by ICH M11 Value Sets.\nThese should all be moved into tx.fhir.org but are included here for testing and validation.",
  "jurisdiction": [
    {
      "coding": [
        {
          "system": "http://unstats.un.org/unsd/methods/m49/m49.htm",
          "code": "001",
          "display": "World"
        }
      ]
    }
  ],
  "caseSensitive": false,
  "hierarchyMeaning": "part-of",
  "content": "fragment",
  "concept": [
    {
      "code": "C20189",
      "display": "Property or Attribute",
      "definition": "A distinguishing quality or prominent aspect of a person, object, action, process, or substance.",
      "concept": [
        {
          "code": "C48191",
          "display": "Information",
          "definition": "Knowledge derived from study, experience, or instruction that has been gathered or received by communication.",
          "concept": [
            {
              "code": "C60776",
              "display": "Contact Information",
              "definition": "Information regarding the means of contacting a person or group.",
              "concept": [
                {
                  "code": "C218693",
                  "display": "Designated Medical Expert Contact Information",
                  "definition": "The contact information for the sponsor's representative who can advise on specific trial-related medical questions or problems."
                }
              ]
            }
          ]
        },
        {
          "code": "C25162",
          "display": "Code",
          "definition": "A symbol or combination of symbols which is assigned to the members of a collection.",
          "concept": [
            {
              "code": "C20108",
              "display": "Country Code",
              "definition": "An alphanumeric system designed to identify countries. The ISO 3166 standard includes a two letter representation, a three letter representation, and a 3 number representation. The last two are identical to the UN system. The US State Department system maintains a separate two letter representation code set.",
              "concept": [
                {
                  "code": "C54641",
                  "display": "Alpha-2 Country Code",
                  "definition": "The two-letter country codes specified by the ISO 3166-1 country code standard."
                },
                {
                  "code": "C54642",
                  "display": "Alpha-3 Country Code",
                  "definition": "The three-letter country codes specified by the ISO 3166-1 country code standard."
                },
                {
                  "code": "C54640",
                  "display": "Numeric Country Code",
                  "definition": "The numeric, three-digit country codes specified by the ISO 3166-1 country code standard."
                },
                {
                  "code": "C165131",
                  "display": "Study Country Code",
                  "definition": "no definition found"
                }
              ]
            }
          ]
        },
        {
          "code": "C41009",
          "display": "Qualifier",
          "definition": "A term that helps define and render a concept unique.",
          "concept": [
            {
              "code": "C21514",
              "display": "Temporal Qualifier",
              "definition": "Terms used to indicate units of time or other terms associated with time.",
              "concept": [
                {
                  "code": "C25164",
                  "display": "Date",
                  "definition": "The particular day, month and year an event has happened or will happen.",
                  "concept": [
                    {
                      "code": "C71476",
                      "display": "Approval Date",
                      "definition": "A date of an official approbation, recognition, or acceptance as satisfactory.",
                      "concept": [
                        {
                          "code": "C132352",
                          "display": "Protocol Approval by Sponsor Date",
                          "definition": "The date that the sponsor approved a version of the protocol."
                        }
                      ]
                    },
                    {
                      "code": "C93702",
                      "display": "Version Date",
                      "definition": "The date (and time) on which an entity is versioned.",
                      "concept": [
                        {
                          "code": "C93813",
                          "display": "Document Version Date",
                          "definition": "The date on which the document is versioned."
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "code": "C27993",
              "display": "General Qualifier",
              "definition": "A term that helps define and render another concept unique.",
              "concept": [
                {
                  "code": "C17998",
                  "display": "Unknown",
                  "definition": "Not known, observed, recorded; or reported as unknown by the data contributor.",
                  "concept": [
                    {
                      "code": "C150003",
                      "display": "Unknown Transformation",
                      "definition": "It is unknown whether any transformation of the product takes place."
                    }
                  ]
                },
                {
                  "code": "C48655",
                  "display": "Missing Value Reason",
                  "definition": "A specific reason explaining why a meaningful value is not available. A meaningful value answers the question posed by a Data Element Concept. In contrast, a Missing Value Reason answers the implicit question \"Why is there no 'meaningful' value?\", when there is none.",
                  "concept": [
                    {
                      "code": "C48660",
                      "display": "Not Applicable",
                      "definition": "Determination of a value is not relevant in the current context."
                    }
                  ]
                },
                {
                  "code": "C17649",
                  "display": "Other",
                  "definition": "Different than the one(s) previously specified or mentioned."
                },
                {
                  "code": "C68846",
                  "display": "Global",
                  "definition": "Covering or affecting the whole of a system."
                },
                {
                  "code": "C217026",
                  "display": "Not Global",
                  "definition": "Covering or affecting only a portion of the entire system."
                },
                {
                  "code": "C218489",
                  "display": "By Cohort",
                  "definition": "Covering or affecting a cohort of individuals."
                }
              ]
            },
            {
              "code": "C13442",
              "display": "Anatomy Qualifier",
              "definition": "An adjectival term used to specify a region of the body or other concepts associated with the body.",
              "concept": [
                {
                  "code": "C41065",
                  "display": "Locally",
                  "definition": "To a restricted area (of the body)."
                }
              ]
            }
          ]
        },
        {
          "code": "C25341",
          "display": "Location",
          "definition": "A position, site, or point in space where something can be found.",
          "concept": [
            {
              "code": "C222063",
              "display": "Location of Medical Expert Contact Information",
              "definition": "The physical or virtual location of the medical expert (as designated by the sponsor) contact information."
            },
            {
              "code": "C218484",
              "display": "Location of Sponsor Approval Date",
              "definition": "The physical or virtual location of the date on which the sponsor approved the current version of the protocol."
            },
            {
              "code": "C222064",
              "display": "Location of Sponsor Signatory Information",
              "definition": "The physical or virtual location of the sponsor signatory information."
            }
          ]
        }
      ]
    },
    {
      "code": "C43431",
      "display": "Activity",
      "definition": "An active process; excludes processes and mechanisms which fulfill biological functions.",
      "concept": [
        {
          "code": "C16326",
          "display": "Behavior",
          "definition": "The actions or reactions of an object or organism, usually in relation to the environment or surrounding world of stimuli.",
          "concept": [
            {
              "code": "C16452",
              "display": "Communication",
              "definition": "The exchange of information between objects, people, or groups.",
              "concept": [
                {
                  "code": "C82658",
                  "display": "Communication Response",
                  "definition": "A statement (either spoken or written) that is made in reply to a question, request, criticism, or accusation.",
                  "concept": [
                    {
                      "code": "C49149",
                      "display": "Answer",
                      "definition": "A statement (either spoken or written) that is made in reply to a question or request or criticism or accusation; a statement that solves a problem or explains how to solve the problem.",
                      "concept": [
                        {
                          "code": "C49487",
                          "display": "No",
                          "definition": "The non-affirmative response to a question."
                        },
                        {
                          "code": "C49488",
                          "display": "Yes",
                          "definition": "The affirmative response to a question."
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "code": "C19683",
              "display": "Personal Behavior",
              "definition": "The observable response of a person.",
              "concept": [
                {
                  "code": "C16735",
                  "display": "Informed Consent",
                  "definition": "Consent by a patient to a surgical or medical procedure or participation in a clinical study after achieving an understanding of the relevant medical facts and the risks involved."
                }
              ]
            }
          ]
        },
        {
          "code": "C16203",
          "display": "Clinical or Research Activity",
          "definition": "Any specific activity undertaken during the course of a clinical study or research protocol.",
          "concept": [
            {
              "code": "C15429",
              "display": "Research Activity",
              "definition": "Systematic investigation into a subject in order to discover facts, establish or revise a theory, or develop a plan of action based on the facts discovered.",
              "concept": [
                {
                  "code": "C63536",
                  "display": "Study",
                  "definition": "A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.",
                  "concept": [
                    {
                      "code": "C15206",
                      "display": "Clinical Study",
                      "definition": "Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.",
                      "concept": [
                        {
                          "code": "C208216",
                          "display": "Clinical Study by Type",
                          "definition": "A clinical study classified by its type, such as observational studies, case-control studies, cohort studies, cross-sectional studies, and clinical trials.",
                          "concept": [
                            {
                              "code": "C71104",
                              "display": "Clinical Trial",
                              "definition": "A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.",
                              "concept": [
                                {
                                  "code": "C70820",
                                  "display": "Clinical Trial by Phase",
                                  "definition": "A description of a clinical trial by the phase of the trial (I, II, III, or IV).",
                                  "concept": [
                                    {
                                      "code": "C54721",
                                      "display": "Early Phase 1 Trial",
                                      "definition": "Exploratory clinical trials, in a small number of participants, that are conducted early in Phase 1. The investigational trial intervention is administered at a low dose for a limited time. Early Phase 1 trials provide insights into a variety of parameters such as pharmacokinetic, pharmacodynamic, and other biomarkers. They involve limited human exposure, have no therapeutic or diagnostic intent, and are not intended to assess clinical tolerability."
                                    },
                                    {
                                      "code": "C15600",
                                      "display": "Phase I Trial",
                                      "definition": "Exploratory clinical trials that may be first-in-human, conducted in a small number of patients or healthy volunteers to evaluate clinical safety, tolerability, or therapeutic intent (pharmacokinetics and pharmacodynamics) of an investigational trial intervention.",
                                      "concept": [
                                        {
                                          "code": "C142564",
                                          "display": "First-in-Human Study",
                                          "definition": "A type of phase 1 clinical trial in which the test product is administered to human beings for the first time."
                                        },
                                        {
                                          "code": "C199990",
                                          "display": "Phase Ia Trial",
                                          "definition": "A type of phase 1 trial with a single ascending dose (dose escalation) in a small group of patients (in comparison to a Phase 1b)."
                                        },
                                        {
                                          "code": "C199989",
                                          "display": "Phase Ib Trial",
                                          "definition": "A type of phase 1 trial with multiple ascending doses (dose expansion) in a larger group of patients (in comparison to a Phase 1a)."
                                        }
                                      ]
                                    },
                                    {
                                      "code": "C15693",
                                      "display": "Phase I/II Trial",
                                      "definition": "A single clinical trial that combines elements of Phase 1 and Phase 2 trials, which may begin as a Phase 1 trial and transition into Phase 2 based upon predetermined criteria.",
                                      "concept": [
                                        {
                                          "code": "C15835",
                                          "display": "Phase I and II Vaccine Trials",
                                          "definition": "Select candidate vaccines or concepts suitable for Phase I and Phase II trials and conduct these trials."
                                        }
                                      ]
                                    },
                                    {
                                      "code": "C198366",
                                      "display": "Phase I/II/III Trial",
                                      "definition": "A study that begins as a Phase I study and transitions into Phases II and III based upon successful completion of each previous portion."
                                    },
                                    {
                                      "code": "C198367",
                                      "display": "Phase I/III Trial",
                                      "definition": "A study that begins as a Phase I study and transitions into a Phase III study upon successful completion of the Phase I portion."
                                    },
                                    {
                                      "code": "C15601",
                                      "display": "Phase II Trial",
                                      "definition": "Exploratory trials conducted to evaluate the safety and efficacy of the investigational trial intervention in patients with the disease or condition. Objectives may include, but are not limited to, clinical pharmacology, dose-ranging (dose-response, frequency of dosing), type of patients, or other characteristics of safety and efficacy.",
                                      "concept": [
                                        {
                                          "code": "C49686",
                                          "display": "Phase IIa Trial",
                                          "definition": "A clinical research protocol generally referred to as a pilot or feasibility trial that aims to prove the concept of the new intervention in question."
                                        },
                                        {
                                          "code": "C49688",
                                          "display": "Phase IIb Trial",
                                          "definition": "A clinical research protocol generally referred to as a well-controlled and pivotal trial that aims to prove the mechanism of action of the new intervention in question. A pivotal study will generally be well-controlled, randomized, of adequate size, and whenever possible, double-blind."
                                        }
                                      ]
                                    },
                                    {
                                      "code": "C15694",
                                      "display": "Phase II/III Trial",
                                      "definition": "A type of clinical study that combines elements characteristic of traditional Phase II and Phase III trials."
                                    },
                                    {
                                      "code": "C217024",
                                      "display": "Phase II/III/IV Trial",
                                      "definition": "A study that begins as a Phase II study and transitions into Phases III and IV based upon successful completion of each previous portion."
                                    },
                                    {
                                      "code": "C15602",
                                      "display": "Phase III Trial",
                                      "definition": "Confirmatory trials conducted to demonstrate safety, efficacy and tolerability of the investigational trial intervention in patients with the disease or condition. Their objectives are to evaluate the overall benefit-risk relationship and may provide substantial evidence for regulatory approval and product information.",
                                      "concept": [
                                        {
                                          "code": "C15873",
                                          "display": "Phase III Large Scale Vaccine Trial",
                                          "definition": "Select suitable vaccine candidates and support efficacy trials when appropriate criteria are met."
                                        },
                                        {
                                          "code": "C49687",
                                          "display": "Phase IIIa Trial",
                                          "definition": "A classification typically assigned retrospectively to a Phase III trial after regulatory authorities determined the need for a Phase III B trial."
                                        },
                                        {
                                          "code": "C49689",
                                          "display": "Phase IIIb Trial",
                                          "definition": "A type of Phase III trial executed near the time of approval to elicit additional findings. This type of trial may be required as a condition of regulatory authority approval."
                                        }
                                      ]
                                    },
                                    {
                                      "code": "C217025",
                                      "display": "Phase III/IV Trial",
                                      "definition": "A type of clinical study that combines elements characteristic of traditional Phase III and Phase IV trials."
                                    },
                                    {
                                      "code": "C15603",
                                      "display": "Phase IV Trial",
                                      "definition": "Post-approval (or post-marketing) trials conducted to further evaluate the safety and efficacy of an investigational trial intervention in its approved indication and may be conducted to address a regulatory requirement. These studies may explore use of the investigational trial intervention in the real-world setting of clinical practice and may also inform health economics and health technology assessments."
                                    }
                                  ]
                                }
                              ]
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "code": "C16847",
          "display": "Technique",
          "definition": "A practiced and regimented skill or series of actions.",
          "concept": [
            {
              "code": "C20368",
              "display": "Research Technique",
              "definition": "Technique used in the laboratory for scientific research.",
              "concept": [
                {
                  "code": "C60819",
                  "display": "Assay",
                  "definition": "A qualitative or quantitative analysis performed to determine the amount of a particular constituent in a sample or the biological or pharmacological properties or activity of a drug or substance.",
                  "concept": [
                    {
                      "code": "C15958",
                      "display": "In Vitro Assay",
                      "definition": "Assay conducted in an artificial environment, such as in a test tube, under a defined and controlled set of solvent and solute conditions.",
                      "concept": [
                        {
                          "code": "C17635",
                          "display": "Tumor Necrosis Factor Assay",
                          "definition": "An immunoassay to detect Tumor Necrosis Factor (TNF), which is a potent lymphoid factor, and exerts cytotoxic effects on a wide range of tumor cells and other target cells. Utilizes monoclonal antibody to TNF immobilized on microtitre plate."
                        }
                      ]
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    {
      "code": "C20181",
      "display": "Conceptual Entity",
      "definition": "An organizational header for concepts representing mostly abstract entities.",
      "concept": [
        {
          "code": "C19160",
          "display": "Occupation or Discipline",
          "definition": "A grouping of occupations and fields of study.",
          "concept": [
            {
              "code": "C25193",
              "display": "Occupation",
              "definition": "The principal activity that a person does to earn money.",
              "concept": [
                {
                  "code": "C25392",
                  "display": "Manufacturer",
                  "definition": "A person, enterprise, or entity that produces finished goods.",
                  "concept": [
                    {
                      "code": "C156625",
                      "display": "Device Manufacture",
                      "definition": "A person or entity that designs, manufactures, fabricates, assembles, or processes a finished device."
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "code": "C49154",
          "display": "Statement",
          "definition": "A verbal and/or written message that asserts, affirms, or declares something.",
          "concept": [
            {
              "code": "C218474",
              "display": "Protocol Amendment Details Statement",
              "definition": "no definition found",
              "concept": [
                {
                  "code": "C218485",
                  "display": "Protocol Not Amended",
                  "definition": "This protocol has not been amended."
                },
                {
                  "code": "C218488",
                  "display": "Protocol Previously Amended See Summary of Changes Before the Table of Contents",
                  "definition": "This protocol has been amended previously. The Protocol Amendment Summary of Changes for the current amendment is located directly before the Table of Contents. Prior amendment(s) to this protocol are listed in the table below, beginning with the most recent."
                },
                {
                  "code": "C218487",
                  "display": "Protocol Previously Amended, Details Presented",
                  "definition": "This protocol has been amended previously. Details of prior amendments are presented in Section 12.3 Prior Protocol Amendment(s)."
                },
                {
                  "code": "C218486",
                  "display": "First Protocol Amendment",
                  "definition": "This is the first protocol amendment."
                }
              ]
            }
          ]
        },
        {
          "code": "C25180",
          "display": "Indicator",
          "definition": "An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.",
          "concept": [
            {
              "code": "C218673",
              "display": "Amendment Scope Global Applicability Indicator",
              "definition": "A descriptive indicator of whether the amendment scope applies globally across the trial."
            },
            {
              "code": "C218672",
              "display": "Original Protocol Indicator",
              "definition": "An indication as to whether the protocol document reflects the original version of the protocol."
            }
          ]
        },
        {
          "code": "C25257",
          "display": "Phase",
          "definition": "A distinguishable part, a stage in a series of events or in a process of development, e.g. any of the varying aspects or stages in course of a disease; a fraction of a cycle.",
          "concept": [
            {
              "code": "C48281",
              "display": "Trial Phase",
              "definition": "Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed."
            }
          ]
        },
        {
          "code": "C25638",
          "display": "Reason",
          "definition": "An explanation of the cause of some phenomenon or action.",
          "concept": [
            {
              "code": "C207457",
              "display": "Study Amendment Reason",
              "definition": "The rationale for the change(s) to, or formal clarification of, a protocol.",
              "concept": [
                {
                  "code": "C218497",
                  "display": "Change in Standard Of Care Amendment Reason",
                  "definition": "A change in the standard of care necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                  "code": "C218496",
                  "display": "Change in Strategy Amendment Reason",
                  "definition": "A change in the study purpose or intent of the scientific plan necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                  "code": "C218495",
                  "display": "IMP Addition Amendment Reason",
                  "definition": "The addition of an investigational medicinal product to a clinical trial design necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                  "code": "C218501",
                  "display": "Inconsistency and/or Error in the Protocol Amendment Reason",
                  "definition": "An error or inconsistency in the protocol necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                  "code": "C218499",
                  "display": "Investigator/Site Feedback Amendment Reason",
                  "definition": "Feedback from the investigator or study site necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                  "code": "C218492",
                  "display": "IRB/IEC Feedback Amendment Reason",
                  "definition": "Feedback from the institutional review board or independent ethics committee necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                  "code": "C218494",
                  "display": "Manufacturing Change Amendment Reason",
                  "definition": "A change to manufacturing processes of the study agents necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                  "code": "C218498",
                  "display": "New Data Available (Other Than Safety Data) Amendment Reason",
                  "definition": "Previously unavailable data (other than safety data) becomes available, which necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                  "code": "C218491",
                  "display": "New Regulatory Guidance Amendment Reason",
                  "definition": "A regulatory agency has published a guidance document that necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                  "code": "C218493",
                  "display": "New Safety Information Available Amendment Reason",
                  "definition": "Previously unavailable safety data becomes available, which necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                  "code": "C218502",
                  "display": "Protocol Design Error Amendment Reason",
                  "definition": "A protocol design error necessitates a change(s) to, or formal clarification of, a document."
                },
                {
                  "code": "C218500",
                  "display": "Recruitment Difficulty Amendment Reason",
                  "definition": "Challenges with participant recruitment necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                  "code": "C218490",
                  "display": "Regulatory Agency Request to Amend Amendment Reason",
                  "definition": "A regulatory agency has expressed a need for a change(s) to, or formal clarification of, the protocol."
                }
              ]
            }
          ]
        },
        {
          "code": "C25190",
          "display": "Person",
          "definition": "A human being.",
          "concept": [
            {
              "code": "C198995",
              "display": "Person by OccupationType",
              "definition": "An individual who is classified by their work type.",
              "concept": [
                {
                  "code": "C17445",
                  "display": "Caregiver",
                  "definition": "The primary person in charge of the care of a patient, usually a family member or a designated health care professional.",
                  "concept": [
                    {
                      "code": "C53427",
                      "display": "Other Caregiver",
                      "definition": "Different from the previously specified or mentioned type of person who has primary responsibility for the assistance and supervision for an individual."
                    }
                  ]
                }
              ]
            },
            {
              "code": "C198997",
              "display": "Person by Activity Type",
              "definition": "A person described by an activity with which they are engaged.",
              "concept": [
                {
                  "code": "C48355",
                  "display": "Sponsor",
                  "definition": "A person or organization that supports or champions something.",
                  "concept": [
                    {
                      "code": "C71136",
                      "display": "Regulatory Application Sponsor",
                      "definition": "The party who submits a marketing application to FDA for approval of a drug, device, or biologic product. An applicant is the person or entity who assumes responsibility for the marketing of a new medical product, including responsibility for compliance with applicable provisions of the Federal Food, Drug, and Cosmetic Act and related regulations. The sponsor is usually an individual, partnership, corporation, government agency, manufacturer or scientific institution."
                    },
                    {
                      "code": "C142679",
                      "display": "Secondary Sponsor",
                      "definition": "Additional individuals, organizations or other legal persons, if any, that have agreed with the primary sponsor to take on sponsorship responsibilities. (WHO)"
                    },
                    {
                      "code": "C93478",
                      "display": "Study Legal Sponsor",
                      "definition": "A sponsor that initiates the investigation and is legally responsible for the study."
                    },
                    {
                      "code": "C215669",
                      "display": "Study Co-Sponsor",
                      "definition": "An individual, company, institution, or organization that is designated by the study sponsor as a vested partner in the study."
                    },
                    {
                      "code": "C215670",
                      "display": "Local Legal Sponsor",
                      "definition": "The sponsor's legal representative at a geographical region within which the sponsor has no legal presence. (ICH M11)"
                    },
                    {
                      "code": "C70793",
                      "display": "Clinical Study Sponsor",
                      "definition": "An individual, company, institution, or organization that takes responsibility for the initiation, management, and/or financing of a clinical study. (CDISC Glossary)",
                      "concept": [
                        {
                          "code": "C187708",
                          "display": "Commercial Clinical Trial Sponsor",
                          "definition": "A person or organization that takes responsibility for a trial which is part of the development program for a marketing authorization of a medicinal product at the time of the application. (EUDRACT)"
                        },
                        {
                          "code": "C187709",
                          "display": "Non-commercial Clinical Trial Sponsor",
                          "definition": "A person or organization that takes responsibility for a trial that is not part of the development program for a marketing authorization of a medicinal product at the time of the application. (EUDRACT)"
                        },
                        {
                          "code": "C70794",
                          "display": "Primary Clinical Study Sponsor",
                          "definition": "The individual, organization, group or other legal person taking responsibility for securing the arrangements to initiate and/or manage a study (including arrangements to ensure that the study design meets appropriate standards and to ensure appropriate conduct and reporting). In commercial trials, the primary sponsor is normally the main applicant for regulatory authorization to begin the study. It may or may not be the main funder."
                        },
                        {
                          "code": "C70795",
                          "display": "Secondary Clinical Study Sponsor",
                          "definition": "Additional individuals, organizations or other legal persons, if any, that have agreed with the primary sponsor to take on responsibilities of sponsorship. A secondary sponsor may have agreed -to take on all the responsibilities of sponsorship jointly with the primary sponsor; or to form a group with the primary sponsor in which the responsibilities of sponsorship are allocated among the members of the group; or to act as the sponsor's legal representative in relation to some or all of the study sites; or to take responsibility for the accuracy of study registration information submitted."
                        }
                      ]
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "code": "C43359",
          "display": "Group",
          "definition": "Any number of entities (members) considered as a unit.",
          "concept": [
            {
              "code": "C17005",
              "display": "Population Group",
              "definition": "A group of individuals united by a common factor (e.g., geographic location, ethnicity, disease, age, sex).",
              "concept": [
                {
                  "code": "C60758",
                  "display": "Personnel",
                  "definition": "Persons employed in any field.",
                  "concept": [
                    {
                      "code": "C17089",
                      "display": "Research Personnel",
                      "definition": "People engaged in research.",
                      "concept": [
                        {
                          "code": "C51876",
                          "display": "Sponsor Medical Expert",
                          "definition": "A physician or health care provider selected by the sponsor to be readily available to advise clinical trial officials on trial related medical questions or problems."
                        },
                        {
                          "code": "C51824",
                          "display": "Evaluator",
                          "definition": "A person who determines the significance, worth, or condition of something by careful appraisal and study.",
                          "concept": [
                            {
                              "code": "C207599",
                              "display": "Outcomes Assessor",
                              "definition": "The individual who evaluates the outcome(s) of interest."
                            }
                          ]
                        },
                        {
                          "code": "C25936",
                          "display": "Investigator",
                          "definition": "An individual who conducts scientific research. In a clinical setting this individual actually conducts and/or supervises the clinical investigation and study-related procedures.  The investigator monitors the safety of the trial subjects and investigational staff (under whose immediate direction an agent is administered or dispensed to a subject).  The investigator collects and analyses data and study documents, and provides reports in compliance with applicable requirements.",
                          "concept": [
                            {
                              "code": "C70722",
                              "display": "Investigator by Role in Study",
                              "definition": "The characteristic that defines the responsibility of the investigator on a particular study.",
                              "concept": [
                                {
                                  "code": "C51812",
                                  "display": "Co-Investigator",
                                  "definition": "One of two or more scientists working together on a research project. A person that equally contributes to the preparation of the protocol, and shares the responsibilities of this position, including medical monitoring (particularly toxicity/safety), liaison with statisticians over analysis, and the generation of a report containing the results."
                                },
                                {
                                  "code": "C51818",
                                  "display": "Coordinating Investigator",
                                  "definition": "A research scientist whose task is to see that work, or events, goes harmoniously.",
                                  "concept": [
                                    {
                                      "code": "C154706",
                                      "display": "National Coordinating Investigator",
                                      "definition": "In the case of a multinational study, a person who has the responsibilities of the sponsor of the study in his/her country and will be responsible for the coordination of the principal investigators at different sites within that member state. (EMA)"
                                    }
                                  ]
                                },
                                {
                                  "code": "C51825",
                                  "display": "Grant Investigator",
                                  "definition": "An individual designated by the grantee to take part in the conduction of the study or to participate in a scientific activity being supported by the grant."
                                },
                                {
                                  "code": "C19924",
                                  "display": "Principal Investigator",
                                  "definition": "An investigator who is responsible for all aspects of the conduct of a study.",
                                  "concept": [
                                    {
                                      "code": "C51817",
                                      "display": "Contract Principal Investigator",
                                      "definition": "A scientist or health care professional that has a financial agreement, as outlined in a binding statement of work, with the sponsor to bear full and ultimate responsibility for the scientific, administrative, ethical, legal, technical, and fiscal aspects of the study, and for day-to-day management of the scientific project, as well as for documenting and reporting its results."
                                    },
                                    {
                                      "code": "C63403",
                                      "display": "Funded Principal Investigator",
                                      "definition": "The investigator named on the award document.  This investigator has full and ultimate responsibility for all research conducted under the award."
                                    },
                                    {
                                      "code": "C51826",
                                      "display": "Grant Principal Investigator",
                                      "definition": "An individual designated by the grantee to direct the project or activity being supported by the grant. He or she is responsible for the scientific, legal, administrative, and technical aspects of the grant and accountable to the grantee for the proper conduct of the project or activity. The Principle Investigator (PI) must have a formal written appointment with the applicant organization, which must be in the form of an official relationship between the parties, but need not involve a salary or other form of remuneration. The PI is a member of the grantee team responsible for ensuring compliance with the financial and administrative aspects of the award and with organizational as well as Federal requirements."
                                    }
                                  ]
                                },
                                {
                                  "code": "C51856",
                                  "display": "Protocol Lead Investigator",
                                  "definition": "Primary clinical researcher of a clinical trial, ultimately responsible for all aspects in the conduct of a study, but has special responsibility with regard to the implementation and administration of the study design, and methodology of a trial."
                                },
                                {
                                  "code": "C51875",
                                  "display": "Site Representative Investigator",
                                  "definition": "The investigator who officially represents a clinical site that participates in a multicentral clinical trial. The responsibilities of the official include the management of site compliance with rules and regulations and attention to personnel and patient requisites."
                                },
                                {
                                  "code": "C54622",
                                  "display": "Subinvestigator",
                                  "definition": "Any individual member of the clinical trial team designated and supervised by the investigator at a trial site to perform critical trial-related procedures and/or to make important trial-related decisions (e.g., associates, residents, research fellows)."
                                }
                              ]
                            },
                            {
                              "code": "C214478",
                              "display": "Non-Physician Investigator",
                              "definition": "A researcher who does not have a degree in medicine."
                            },
                            {
                              "code": "C93404",
                              "display": "Study Site Investigator",
                              "definition": "A researcher at a study site who oversees multiple aspects of the study at a site, including protocol submission for IRB approval, participant recruitment, informed consent, data collection, and analysis."
                            },
                            {
                              "code": "C198656",
                              "display": "Treating Investigator",
                              "definition": "The study investigator in charge of administering treatment to study participants."
                            }
                          ]
                        }
                      ]
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "code": "C48910",
          "display": "Subject",
          "definition": "Some matter, situation, or event that is thought about, written about, or discussed.",
          "concept": [
            {
              "code": "C79916",
              "display": "Investigative Subject",
              "definition": "An entity, either biologic or otherwise, of interest in an investigation.",
              "concept": [
                {
                  "code": "C41189",
                  "display": "Study Subject",
                  "definition": "A matter or an individual that is observed, analyzed, examined, investigated, experimented upon, or/and treated in the course of a particular study.",
                  "concept": [
                    {
                      "code": "C142710",
                      "display": "Study Participant",
                      "definition": "Any individiual that has a role in a study, including study personnel and study subjects.",
                      "concept": [
                        {
                          "code": "C188266",
                          "display": "High Risk Study Participant",
                          "definition": "A participant in a study that presents a greater than moderate risk due to the increased probability for generating serious adverse events. Since there is a probability of an event that is serious and prolonged or permanent occurring as a result of study participation, the participant will require high intensity monitoring."
                        }
                      ]
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "code": "C25198",
          "display": "Record",
          "definition": "Anything (e.g., a document) providing permanent evidence of or information about past events.",
          "concept": [
            {
              "code": "C19498",
              "display": "Document",
              "definition": "A physical object, or electronic counterpart, that is characterized by containing writing which is meant to be human-readable.",
              "concept": [
                {
                  "code": "C42651",
                  "display": "Protocol",
                  "definition": "A rule which guides how an activity should be performed.",
                  "concept": [
                    {
                      "code": "C70705",
                      "display": "Component of Study Protocol",
                      "definition": "A component of a plan on which a study is based.",
                      "concept": [
                        {
                          "code": "C181183",
                          "display": "Protocol Statement",
                          "definition": "A written message providing an official assurance, account, or assertion within the study protocol.",
                          "concept": [
                            {
                              "code": "C181236",
                              "display": "Protocol Confidentiality Statement",
                              "definition": "A written message within the study protocol that asserts a statement of non-disclosure, such that information contained within the protocol document may only be shared with authorized parties."
                            }
                          ]
                        }
                      ]
                    }
                  ]
                },
                {
                  "code": "C25678",
                  "display": "Signature",
                  "definition": "Individual's name or personal mark, used to sign documents and employed to signify that the writing which precedes accords with one's wishes and intentions; having a handwritten signature.",
                  "concept": [
                    {
                      "code": "C222014",
                      "display": "Sponsor Signatory",
                      "definition": "A block of text containing the name and signature of the sponsor's signatory, along with the signature date."
                    }
                  ]
                },
                {
                  "code": "C25364",
                  "display": "Identifier",
                  "definition": "One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.",
                  "concept": [
                    {
                      "code": "C83081",
                      "display": "Study Site Identifier",
                      "definition": "A sequence of characters used to identify, name, or characterize the study site."
                    },
                    {
                      "code": "C218674",
                      "display": "Region Identifier",
                      "definition": "A sequence of characters used to identify and/or name the region."
                    },
                    {
                      "code": "C218690",
                      "display": "Other Regulatory or Clinical Trial Identifier",
                      "definition": "A sequence of characters assigned by a regulatory agency or other health authority that is used to identify a clinical trial, and that is different than the one(s) previously specified or mentioned."
                    },
                    {
                      "code": "C96095",
                      "display": "Product Identifier",
                      "definition": "no definition found",
                      "concept": [
                        {
                          "code": "C218675",
                          "display": "Sponsor's Investigational Product Code",
                          "definition": "A symbol or combination of symbols that are assigned by the sponsor to uniquely identify an experimental intervention."
                        }
                      ]
                    },
                    {
                      "code": "C70663",
                      "display": "Unique Identifier",
                      "definition": "A set of characters used as a code that is unique in the context or the system for which it is created. It serves as a means of identification and reference (often instead of a name) for an entity, person, thing, function, procedure, activity, variable, or body of data.",
                      "concept": [
                        {
                          "code": "C98714",
                          "display": "Clinical Trial Registry Identifier",
                          "definition": "A sequence of letters, numbers, or other characters that uniquely identifies a clinical trial within a clinical trial registry.",
                          "concept": [
                            {
                              "code": "C172240",
                              "display": "Clinicaltrials.gov Identifier",
                              "definition": "The unique alphanumeric identifier for a trial as assigned by the Clinicaltrials.gov Protocol Registration and Results System (PRS).",
                              "concept": [
                                {
                                  "code": "C127792",
                                  "display": "Clinicaltrials.gov NCT Number for the Expanded Access Record",
                                  "definition": "The unique alphanumeric identifier for a study with associated expanded access record, as assigned by the clinicaltrials.gov PRS system."
                                }
                              ]
                            }
                          ]
                        }
                      ]
                    },
                    {
                      "code": "C132299",
                      "display": "Protocol Identifier",
                      "definition": "A sequence of letters, numbers, or other characters that uniquely identifies a study protocol.",
                      "concept": [
                        {
                          "code": "C132351",
                          "display": "Sponsor Protocol Identifier",
                          "definition": "A unique code, which is assigned by the sponsor, that identifies a specific protocol."
                        }
                      ]
                    },
                    {
                      "code": "C218689",
                      "display": "WHO/UTN Number",
                      "definition": "A sequence of characters used to identify a clinical trial, as assigned by the World Health organization's International Clinical Trial's Registry Platform (ICTRP)."
                    },
                    {
                      "code": "C218477",
                      "display": "Amendment Identifier",
                      "definition": "A sequence of characters used to uniquely identify a protocol amendment."
                    },
                    {
                      "code": "C218688",
                      "display": "NMPA IND Number",
                      "definition": "A sequence of characters used to identify a clinical trial under an Investigational New Drug (IND) application, as assigned by the Chinese National Medicinal Products Administration (NMPA)."
                    },
                    {
                      "code": "C218686",
                      "display": "US FDA Investigational Device Exemption Application Number",
                      "definition": "A sequence of characters used to identify a clinical trial under an Investigational Device Exemption (IDE) application, as assigned by the US Food and Drug Administration."
                    },
                    {
                      "code": "C218684",
                      "display": "EU Clinical Trial Register Number",
                      "definition": "A sequence of characters used to identify a clinical trial, as assigned by the Clinical Trials Information System (CTIS) of the European Medicines Agency."
                    },
                    {
                      "code": "C218687",
                      "display": "Japan Registry for Clinical Trials Number",
                      "definition": "A sequence of characters used to identify a clinical trial, as assigned by the Japan Registry for Clinical Trials (JRCT) of the Ministry of Health, Labour and Welfare (MHLW) in Japan."
                    },
                    {
                      "code": "C218685",
                      "display": "US FDA Investigational New Drug Application Number",
                      "definition": "A sequence of characters used to identify a clinical trial under an Investigational New Drug (IND) application, as assigned by the US Food and Drug Administration."
                    }
                  ]
                },
                {
                  "code": "C25704",
                  "display": "Text",
                  "definition": "The words of something written.",
                  "concept": [
                    {
                      "code": "C207508",
                      "display": "Narrative Content Text",
                      "definition": "A textual representation of the narrative content."
                    },
                    {
                      "code": "C93703",
                      "display": "Version Number Text",
                      "definition": "A numeric character string that identifies a form or variant of a type or original.",
                      "concept": [
                        {
                          "code": "C181232",
                          "display": "Study Protocol Version Number",
                          "definition": "A string of numerals that uniquely identifies a specific version of a study protocol."
                        }
                      ]
                    }
                  ]
                },
                {
                  "code": "C25407",
                  "display": "Address",
                  "definition": "A standardized representation of the location of a person, business, building, or organization.",
                  "concept": [
                    {
                      "code": "C70946",
                      "display": "Postal Address",
                      "definition": "A physical location used by a person or organization for the purpose of receiving postal mail deliveries.",
                      "concept": [
                        {
                          "code": "C93844",
                          "display": "Health Care Provider Postal Address",
                          "definition": "A contact point used to send physical forms of communication to the healthcare provider."
                        },
                        {
                          "code": "C93847",
                          "display": "Healthcare Facility Postal Address",
                          "definition": "A contact point used to send physical forms of communication to the healthcare facility."
                        },
                        {
                          "code": "C164841",
                          "display": "Insured Person Postal Address",
                          "definition": "no definition found"
                        },
                        {
                          "code": "C93875",
                          "display": "Organization Postal Address",
                          "definition": "A contact point used to send physical forms of communication to the organization."
                        },
                        {
                          "code": "C164888",
                          "display": "Organization Staff Role Postal Address",
                          "definition": "no definition found"
                        },
                        {
                          "code": "C93880",
                          "display": "Organizational Contact Postal Address",
                          "definition": "A contact point used to send physical forms of communication to the organizational contact."
                        },
                        {
                          "code": "C93983",
                          "display": "Performer Postal Address",
                          "definition": "A contact point used to send physical forms of communication to the performer."
                        },
                        {
                          "code": "C93990",
                          "display": "Person Postal Address",
                          "definition": "A contact point used to send physical forms of communication to the person."
                        },
                        {
                          "code": "C165044",
                          "display": "Point Of Contact Postal Address",
                          "definition": "no definition found"
                        },
                        {
                          "code": "C94065",
                          "display": "Research Staff Postal Address",
                          "definition": "A contact point used to send physical forms of communication to the research staff."
                        },
                        {
                          "code": "C95395",
                          "display": "Service Delivery Location Postal Address",
                          "definition": "The postal address of the service delivery location."
                        },
                        {
                          "code": "C176376",
                          "display": "Study Contact Postal Address",
                          "definition": "A physical location used by a study contact for the purpose of receiving postal mail deliveries."
                        },
                        {
                          "code": "C165133",
                          "display": "Study Country Personnel Postal Address",
                          "definition": "no definition found"
                        },
                        {
                          "code": "C94101",
                          "display": "Study Personnel Postal Address",
                          "definition": "A contact point used to send physical forms of communication to the study personnel."
                        },
                        {
                          "code": "C94147",
                          "display": "Study Site Personnel Postal Address",
                          "definition": "A contact point used to send physical forms of communication to the study site personnel."
                        }
                      ]
                    },
                    {
                      "code": "C218677",
                      "display": "Sponsor Legal Address",
                      "definition": "The legally registered address of the trial sponsor."
                    },
                    {
                      "code": "C218679",
                      "display": "Co-Sponsor Legal Address",
                      "definition": "The legally registered address of the trial co-sponsor."
                    },
                    {
                      "code": "C218683",
                      "display": "Device Manufacturer Legal Address",
                      "definition": "The legally registered address of the device manufacturer."
                    },
                    {
                      "code": "C218681",
                      "display": "Local Sponsor Legal Address",
                      "definition": "The legally registered address of the sponsor's legal representative at a geographical region within which the sponsor has no legal presence."
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "code": "C25480",
          "display": "Details",
          "definition": "Particulars considered individually and in relation to a whole.",
          "concept": [
            {
              "code": "C218694",
              "display": "Protocol Amendment Details",
              "definition": "Particulars about the protocol amendment, considered individually and in relation to a whole."
            }
          ]
        },
        {
          "code": "C42614",
          "display": "Name",
          "definition": "The words or language units by which a thing is known.",
          "concept": [
            {
              "code": "C218678",
              "display": "Co-Sponsor Name",
              "definition": "The literal identifier (i.e., distinctive designation) of the trial co-sponsor."
            },
            {
              "code": "C218682",
              "display": "Device Manufacturer Name",
              "definition": "The literal identifier (i.e., distinctive designation) of the organization defined as being responsible for creating the device as stated on the package in which the product is supplied."
            },
            {
              "code": "C218680",
              "display": "Local Sponsor Name",
              "definition": "The literal identifier (i.e., distinctive designation) of the sponsor's legal representative at a geographical region within which the sponsor has no legal presence."
            },
            {
              "code": "C222495",
              "display": "Trial Sponsor Name",
              "definition": "The literal identifier (i.e., distinctive designation) of the trial sponsor."
            },
            {
              "code": "C42774",
              "display": "Title",
              "definition": "An official descriptive name of a document, e.g. the long name of a study protocol provided by the study sponsor.",
              "concept": [
                {
                  "code": "C132300",
                  "display": "Protocol Title",
                  "definition": "The name of a study protocol.",
                  "concept": [
                    {
                      "code": "C132346",
                      "display": "Official Protocol Title",
                      "definition": "The formal, descriptive name of the protocol."
                    }
                  ]
                },
                {
                  "code": "C93637",
                  "display": "Public Title",
                  "definition": "The title of the document intended for the general population.",
                  "concept": [
                    {
                      "code": "C94105",
                      "display": "Study Protocol Document Version Public Title",
                      "definition": "The short descriptive name for the trial."
                    }
                  ]
                },
                {
                  "code": "C49802",
                  "display": "Trial Title",
                  "definition": "The name of a clinical trial.",
                  "concept": [
                    {
                      "code": "C207615",
                      "display": "Brief Study Title",
                      "definition": "The short descriptive name for the study."
                    },
                    {
                      "code": "C207618",
                      "display": "Scientific Study Title",
                      "definition": "A more extensive descriptive name of the study that is intended for medical professionals, written using medical and scientific language."
                    },
                    {
                      "code": "C207616",
                      "display": "Official Study Title",
                      "definition": "The formal descriptive name for the study."
                    },
                    {
                      "code": "C207617",
                      "display": "Public Study Title",
                      "definition": "The descriptive name of the study that is intended for the lay public, written in easily understood language."
                    }
                  ]
                }
              ]
            },
            {
              "code": "C93495",
              "display": "Acronym",
              "definition": "The non-unique initials or abbreviated name used for identification.",
              "concept": [
                {
                  "code": "C94108",
                  "display": "Study Protocol Version Acronym",
                  "definition": "The non-unique initials or abbreviated name used for identification of the study protocol document version."
                },
                {
                  "code": "C207646",
                  "display": "Study Acronym",
                  "definition": "The non-unique initials or abbreviated name used for identification of the study."
                }
              ]
            },
            {
              "code": "C71898",
              "display": "Proprietary Name",
              "definition": "The part of the name or logo associated with a specific product or service identifying and distinguishing it from varieties of the same product or service marketed by competing companies."
            },
            {
              "code": "C97054",
              "display": "Generic Name",
              "definition": "Drug name that is not protected by a trademark, usually descriptive of its chemical structure, and sometimes a public name.",
              "concept": [
                {
                  "code": "C202465",
                  "display": "Compendial Name",
                  "definition": "A name within a pharmaceutical compendium that designates a small or large molecule substance that complies with compendial standards for strength, quality, and purity. (USP Nomenclature Guidelines)"
                },
                {
                  "code": "C142585",
                  "display": "International Nonproprietary Name",
                  "definition": "A unique, internationally consistent and globally recognized name which identifies pharmaceutical substances or active pharmaceutical ingredients and is public property."
                },
                {
                  "code": "C96973",
                  "display": "United States Adopted Name",
                  "definition": "A unique nonproprietary name assigned to drugs and biologics by the United States Adopted Names Council (USAN)."
                },
                {
                  "code": "C203358",
                  "display": "USP-NF Established Name",
                  "definition": "A unique nonproprietary name assigned to drugs and biologics by the United States Pharmacopeia (USP) or excipients by the National Formulary (NF)."
                }
              ]
            }
          ]
        },
        {
          "code": "C19067",
          "display": "Title",
          "definition": "An identifying designation.",
          "concept": [
            {
              "code": "C215610",
              "display": "Document Content Reference Section Title",
              "definition": "An identifying designation for a particular section for the document content reference.",
              "concept": [
                {
                  "code": "C217359",
                  "display": "Protocol Section Title",
                  "definition": "An identifying designation for a section within a protocol document.",
                  "concept": [
                    {
                      "code": "C217360",
                      "display": "ICH M11 Protocol Section Title",
                      "definition": "An identifying designation for a section within the ICH M11 protocol template document.",
                      "concept": [
                        {
                          "code": "C218514",
                          "display": "ICH M11 Protocol Section 1 PROTOCOL SUMMARY",
                          "definition": "The title of section 1 of the ICH M11 protocol guideline: PROTOCOL SUMMARY."
                        },
                        {
                          "code": "C218515",
                          "display": "ICH M11 Protocol Section 1.1 Protocol Synopsis",
                          "definition": "The title of section 1.1 of the ICH M11 protocol guideline: Protocol Synopsis."
                        },
                        {
                          "code": "C218516",
                          "display": "ICH M11 Protocol Section 1.1.1 Primary and Secondary Objectives and Estimands",
                          "definition": "The title of section 1.1.1 of the ICH M11 protocol guideline: Primary and Secondary Objectives and Estimands."
                        },
                        {
                          "code": "C218517",
                          "display": "ICH M11 Protocol Section 1.1.2 Overall Design",
                          "definition": "The title of section 1.1.2 of the ICH M11 protocol guideline: Overall Design."
                        },
                        {
                          "code": "C218518",
                          "display": "ICH M11 Protocol Section 1.2 Trial Schema",
                          "definition": "The title of section 1.2 of the ICH M11 protocol guideline: Trial Schema."
                        },
                        {
                          "code": "C218519",
                          "display": "ICH M11 Protocol Section 1.3 Schedule of Activities",
                          "definition": "The title of section 1.3 of the ICH M11 protocol guideline: Schedule of Activities."
                        },
                        {
                          "code": "C218625",
                          "display": "ICH M11 Protocol Section 10 STATISTICAL CONSIDERATIONS",
                          "definition": "The title of section 10 of the ICH M11 protocol guideline: STATISTICAL CONSIDERATIONS."
                        },
                        {
                          "code": "C218626",
                          "display": "ICH M11 Protocol Section 10.1 General Considerations",
                          "definition": "The title of section 10.1 of the ICH M11 protocol guideline: General Considerations."
                        },
                        {
                          "code": "C218647",
                          "display": "ICH M11 Protocol Section 10.10 Multiplicity Adjustments",
                          "definition": "The title of section 10.10 of the ICH M11 protocol guideline: Multiplicity Adjustments."
                        },
                        {
                          "code": "C218648",
                          "display": "ICH M11 Protocol Section 10.11 Sample Size Determination",
                          "definition": "The title of section 10.11 of the ICH M11 protocol guideline: Sample Size Determination."
                        },
                        {
                          "code": "C218627",
                          "display": "ICH M11 Protocol Section 10.2 Analysis Sets",
                          "definition": "The title of section 10.2 of the ICH M11 protocol guideline: Analysis Sets."
                        },
                        {
                          "code": "C218628",
                          "display": "ICH M11 Protocol Section 10.3 Analyses of Demographics and Other Baseline Variables",
                          "definition": "The title of section 10.3 of the ICH M11 protocol guideline: Analyses of Demographics and Other Baseline Variables."
                        },
                        {
                          "code": "C218629",
                          "display": "ICH M11 Protocol Section 10.4 Analyses Associated with the Primary Objective(s)",
                          "definition": "The title of section 10.4 of the ICH M11 protocol guideline: Analyses Associated with the Primary Objective(s)."
                        },
                        {
                          "code": "C218630",
                          "display": "ICH M11 Protocol Section 10.4.1 Primary Objective",
                          "definition": "The title of section 10.4.1 of the ICH M11 protocol guideline: Primary Objective."
                        },
                        {
                          "code": "C218631",
                          "display": "ICH M11 Protocol Section 10.4.1.1 Statistical Analysis Method",
                          "definition": "The title of section 10.4.1.1 of the ICH M11 protocol guideline: Statistical Analysis Method."
                        },
                        {
                          "code": "C218632",
                          "display": "ICH M11 Protocol Section 10.4.1.2 Handling of Data in Relation to Primary Estimand(s)",
                          "definition": "The title of section 10.4.1.2 of the ICH M11 protocol guideline: Handling of Data in Relation to Primary Estimand(s)."
                        },
                        {
                          "code": "C218633",
                          "display": "ICH M11 Protocol Section 10.4.1.3 Handling of Missing Data in Relation to Primary Estimand(s)",
                          "definition": "The title of section 10.4.1.3 of the ICH M11 protocol guideline: Handling of Missing Data in Relation to Primary Estimand(s)"
                        },
                        {
                          "code": "C218634",
                          "display": "ICH M11 Protocol Section 10.4.1.4 Sensitivity Analysis",
                          "definition": "The title of section 10.4.1.4 of the ICH M11 protocol guideline: Sensitivity Analysis."
                        },
                        {
                          "code": "C218635",
                          "display": "ICH M11 Protocol Section 10.4.1.5 Supplementary Analysis",
                          "definition": "The title of section 10.4.1.5 of the ICH M11 protocol guideline: Supplementary Analysis."
                        },
                        {
                          "code": "C218636",
                          "display": "ICH M11 Protocol Section 10.5 Analyses Associated with the Secondary Objective(s)",
                          "definition": "The title of section 10.5 of the ICH M11 protocol guideline: Analyses Associated with the Secondary Objective(s)."
                        },
                        {
                          "code": "C218637",
                          "display": "ICH M11 Protocol Section 10.5.1 Secondary Objective",
                          "definition": "The title of section 10.5.1 of the ICH M11 protocol guideline: Secondary Objective."
                        },
                        {
                          "code": "C218638",
                          "display": "ICH M11 Protocol Section 10.5.1.1 Statistical Analysis Method",
                          "definition": "The title of section 10.5.1.1 of the ICH M11 protocol guideline: Statistical Analysis Method."
                        },
                        {
                          "code": "C218639",
                          "display": "ICH M11 Protocol Section 10.5.1.2 Handling of Data in Relation to Secondary Estimand(s)",
                          "definition": "The title of section 10.5.1.2 of the ICH M11 protocol guideline: Handling of Data in Relation to Secondary Estimand(s)."
                        },
                        {
                          "code": "C218640",
                          "display": "ICH M11 Protocol Section 10.5.1.3 Handling of Missing Data in Relation to Secondary Estimand(s)",
                          "definition": "The title of section 10.5.1.3 of the ICH M11 protocol guideline: Handling of Missing Data in Relation to Secondary Estimand(s)."
                        },
                        {
                          "code": "C218641",
                          "display": "ICH M11 Protocol Section 10.5.1.4 Sensitivity Analysis",
                          "definition": "The title of section 10.5.1.4 of the ICH M11 protocol guideline: Sensitivity Analysis."
                        },
                        {
                          "code": "C218642",
                          "display": "ICH M11 Protocol Section 10.5.1.5 Supplementary Analysis",
                          "definition": "The title of section 10.5.1.5 of the ICH M11 protocol guideline: Supplementary Analysis."
                        },
                        {
                          "code": "C218643",
                          "display": "ICH M11 Protocol Section 10.6 Analyses Associated with the Exploratory Objective(s)",
                          "definition": "The title of section 10.6 of the ICH M11 protocol guideline: Analyses Associated with the Exploratory Objective(s)."
                        },
                        {
                          "code": "C218644",
                          "display": "ICH M11 Protocol Section 10.7 Safety Analyses",
                          "definition": "The title of section 10.7 of the ICH M11 protocol guideline: Safety Analyses."
                        },
                        {
                          "code": "C218645",
                          "display": "ICH M11 Protocol Section 10.8 Other Analyses",
                          "definition": "The title of section 10.8 of the ICH M11 protocol guideline: Other Analyses."
                        },
                        {
                          "code": "C218646",
                          "display": "ICH M11 Protocol Section 10.9 Interim Analyses",
                          "definition": "The title of section 10.9 of the ICH M11 protocol guideline: Interim Analyses."
                        },
                        {
                          "code": "C218649",
                          "display": "ICH M11 Protocol Section 11 TRIAL OVERSIGHT AND OTHER GENERAL CONSIDERATIONS",
                          "definition": "The title of section 11 of the ICH M11 protocol guideline: TRIAL OVERSIGHT AND OTHER GENERAL CONSIDERATIONS."
                        },
                        {
                          "code": "C218650",
                          "display": "ICH M11 Protocol Section 11.1 Regulatory and Ethical Considerations",
                          "definition": "The title of section 11.1 of the ICH M11 protocol guideline: Regulatory and Ethical Considerations."
                        },
                        {
                          "code": "C218663",
                          "display": "ICH M11 Protocol Section 11.10 Protocol Deviations",
                          "definition": "The title of section 11.10 of the ICH M11 protocol guideline: Protocol Deviations."
                        },
                        {
                          "code": "C218664",
                          "display": "ICH M11 Protocol Section 11.11 Early Site Closure",
                          "definition": "The title of section 11.11 of the ICH M11 protocol guideline: Early Site Closure."
                        },
                        {
                          "code": "C218665",
                          "display": "ICH M11 Protocol Section 11.12 Data Dissemination",
                          "definition": "The title of section 11.12 of the ICH M11 protocol guideline: Data Dissemination."
                        },
                        {
                          "code": "C218651",
                          "display": "ICH M11 Protocol Section 11.2 Trial Oversight",
                          "definition": "The title of section 11.2 of the ICH M11 protocol guideline: Trial Oversight."
                        },
                        {
                          "code": "C218652",
                          "display": "ICH M11 Protocol Section 11.2.1 Investigator Responsibilities",
                          "definition": "The title of section 11.2.1 of the ICH M11 protocol guideline: Investigator Responsibilities."
                        },
                        {
                          "code": "C218653",
                          "display": "ICH M11 Protocol Section 11.2.2 Sponsor Responsibilities",
                          "definition": "The title of section 11.2.2 of the ICH M11 protocol guideline: Sponsor Responsibilities."
                        },
                        {
                          "code": "C218654",
                          "display": "ICH M11 Protocol Section 11.3 Informed Consent Process",
                          "definition": "The title of section 11.3 of the ICH M11 protocol guideline: Informed Consent Process."
                        },
                        {
                          "code": "C218655",
                          "display": "ICH M11 Protocol Section 11.3.1 Informed Consent for Rescreening",
                          "definition": "The title of section 11.3.1 of the ICH M11 protocol guideline: Informed Consent for Rescreening."
                        },
                        {
                          "code": "C218656",
                          "display": "ICH M11 Protocol Section 11.3.2 Informed Consent for Use of Remaining Samples in Exploratory Research",
                          "definition": "The title of section 11.3.2 of the ICH M11 protocol guideline: Informed Consent for Use of Remaining Samples in Exploratory Research."
                        },
                        {
                          "code": "C218657",
                          "display": "ICH M11 Protocol Section 11.4 Committees",
                          "definition": "The title of section 11.4 of the ICH M11 protocol guideline: Committees."
                        },
                        {
                          "code": "C218658",
                          "display": "ICH M11 Protocol Section 11.5 Insurance and Indemnity",
                          "definition": "The title of section 11.5 of the ICH M11 protocol guideline: Insurance and Indemnity."
                        },
                        {
                          "code": "C218659",
                          "display": "ICH M11 Protocol Section 11.6 Risk-Based Quality Management",
                          "definition": "The title of section 11.6 of the ICH M11 protocol guideline: Risk-Based Quality Management."
                        },
                        {
                          "code": "C218660",
                          "display": "ICH M11 Protocol Section 11.7 Data Governance",
                          "definition": "The title of section 11.7 of the ICH M11 protocol guideline: Data Governance."
                        },
                        {
                          "code": "C218661",
                          "display": "ICH M11 Protocol Section 11.8 Data Protection",
                          "definition": "The title of section 11.8 of the ICH M11 protocol guideline: Data Protection."
                        },
                        {
                          "code": "C218662",
                          "display": "ICH M11 Protocol Section 11.9 Source Records",
                          "definition": "The title of section 11.9 of the ICH M11 protocol guideline: Source Records."
                        },
                        {
                          "code": "C218666",
                          "display": "ICH M11 Protocol Section 12 APPENDIX: SUPPORTING DETAILS",
                          "definition": "The title of section 12 of the ICH M11 protocol guideline: APPENDIX: SUPPORTING DETAILS."
                        },
                        {
                          "code": "C218667",
                          "display": "ICH M11 Protocol Section 12.1 Clinical Laboratory Tests",
                          "definition": "The title of section 12.1 of the ICH M11 protocol guideline: Clinical Laboratory Tests."
                        },
                        {
                          "code": "C218668",
                          "display": "ICH M11 Protocol Section 12.2 Country/Region-Specific Differences",
                          "definition": "The title of section 12.2 of the ICH M11 protocol guideline: Country/Region-Specific Differences."
                        },
                        {
                          "code": "C218669",
                          "display": "ICH M11 Protocol Section 12.3 Prior Protocol Amendment(s)",
                          "definition": "The title of section 12.3 of the ICH M11 protocol guideline: Prior Protocol Amendment(s)."
                        },
                        {
                          "code": "C218670",
                          "display": "ICH M11 Protocol Section 13 APPENDIX: GLOSSARY OF TERMS AND ABBREVIATIONS",
                          "definition": "The title of section 13 of the ICH M11 protocol guideline: APPENDIX: GLOSSARY OF TERMS AND ABBREVIATIONS."
                        },
                        {
                          "code": "C218671",
                          "display": "ICH M11 Protocol Section 14 APPENDIX: REFERENCES",
                          "definition": "The title of section 14 of the ICH M11 protocol guideline: APPENDIX: REFERENCES."
                        },
                        {
                          "code": "C218520",
                          "display": "ICH M11 Protocol Section 2 INTRODUCTION",
                          "definition": "The title of section 2 of the ICH M11 protocol guideline: INTRODUCTION."
                        },
                        {
                          "code": "C218521",
                          "display": "ICH M11 Protocol Section 2.1 Purpose of Trial",
                          "definition": "The title of section 2.1 of the ICH M11 protocol guideline: Purpose of Trial."
                        },
                        {
                          "code": "C218522",
                          "display": "ICH M11 Protocol Section 2.2 Assessment of Risks and Benefits",
                          "definition": "The title of section 2.2 of the ICH M11 protocol guideline: Assessment of Risks and Benefits."
                        },
                        {
                          "code": "C218523",
                          "display": "ICH M11 Protocol Section 2.2.1 Risk Summary and Mitigation Strategy",
                          "definition": "The title of section 2.2.2 of the ICH M11 protocol guideline: Risk Summary and Mitigation Strategy."
                        },
                        {
                          "code": "C218524",
                          "display": "ICH M11 Protocol Section 2.2.2 Benefit Summary",
                          "definition": "The title of section 2.2.1 of the ICH M11 protocol guideline: Benefit Summary."
                        },
                        {
                          "code": "C218525",
                          "display": "ICH M11 Protocol Section 2.2.3 Overall Risk-Benefit Assessment",
                          "definition": "The title of section 2.2.3 of the ICH M11 protocol guideline: Overall Risk-Benefit Assessment."
                        },
                        {
                          "code": "C218526",
                          "display": "ICH M11 Protocol Section 3 TRIAL OBJECTIVES AND ASSOCIATED ESTIMANDS",
                          "definition": "The title of section 3 of the ICH M11 protocol guideline: TRIAL OBJECTIVES AND ASSOCIATED ESTIMANDS."
                        },
                        {
                          "code": "C218527",
                          "display": "ICH M11 Protocol Section 3.1 Primary Objective(s) and Associated Estimand(s)",
                          "definition": "The title of section 3.1 of the ICH M11 protocol guideline: Primary Objective(s) and Associated Estimand(s)."
                        },
                        {
                          "code": "C218528",
                          "display": "ICH M11 Protocol Section 3.1.1 Primary Objective",
                          "definition": "The title of section 3.1.1 of the ICH M11 protocol guideline: Primary Objective."
                        },
                        {
                          "code": "C218529",
                          "display": "ICH M11 Protocol Section 3.2 Secondary Objective(s) and Associated Estimand(s)",
                          "definition": "The title of section 3.2 of the ICH M11 protocol guideline: Secondary Objective(s) and Associated Estimand(s)."
                        },
                        {
                          "code": "C218530",
                          "display": "ICH M11 Protocol Section 3.2.1 Secondary Objective",
                          "definition": "The title of section 3.2.1 of the ICH M11 protocol guideline: Secondary Objective."
                        },
                        {
                          "code": "C218531",
                          "display": "ICH M11 Protocol Section 3.3 Exploratory Objective(s)",
                          "definition": "The title of section 3.3 of the ICH M11 protocol guideline: Exploratory Objective(s)."
                        },
                        {
                          "code": "C218532",
                          "display": "ICH M11 Protocol Section 3.3.1 Exploratory Objective",
                          "definition": "The title of section 3.3.1 of the ICH M11 protocol guideline: Exploratory Objective."
                        },
                        {
                          "code": "C218533",
                          "display": "ICH M11 Protocol Section 4 TRIAL DESIGN",
                          "definition": "The title of section 4 of the ICH M11 protocol guideline: TRIAL DESIGN."
                        },
                        {
                          "code": "C218534",
                          "display": "ICH M11 Protocol Section 4.1 Description of Trial Design",
                          "definition": "The title of section 4.1 of the ICH M11 protocol guideline: Description of Trial Design."
                        },
                        {
                          "code": "C218535",
                          "display": "ICH M11 Protocol Section 4.1.1 Stakeholder Input into Design",
                          "definition": "The title of section 4.1.1 of the ICH M11 protocol guideline: Stakeholder Input into Design."
                        },
                        {
                          "code": "C218536",
                          "display": "ICH M11 Protocol Section 4.2 Rationale for Trial Design",
                          "definition": "The title of section 4.2 of the ICH M11 protocol guideline: Rationale for Trial Design."
                        },
                        {
                          "code": "C218537",
                          "display": "ICH M11 Protocol Section 4.2.1 Rationale for Estimand(s)",
                          "definition": "The title of section 4.2.1 of the ICH M11 protocol guideline: Rationale for Estimand(s)."
                        },
                        {
                          "code": "C218538",
                          "display": "ICH M11 Protocol Section 4.2.2 Rationale for Intervention Model",
                          "definition": "The title of section 4.2.2 of the ICH M11 protocol guideline: Rationale for Intervention Model."
                        },
                        {
                          "code": "C218539",
                          "display": "ICH M11 Protocol Section 4.2.3 Rationale for Control Type",
                          "definition": "The title of section 4.2.3 of the ICH M11 protocol guideline: Rationale for Control Type."
                        },
                        {
                          "code": "C218540",
                          "display": "ICH M11 Protocol Section 4.2.4 Rationale for Trial Duration",
                          "definition": "The title of section 4.2.4 of the ICH M11 protocol guideline: Rationale for Trial Duration."
                        },
                        {
                          "code": "C218541",
                          "display": "ICH M11 Protocol Section 4.2.5 Rationale for Adaptive or Novel Trial Design",
                          "definition": "The title of section 4.2.5 of the ICH M11 protocol guideline: Rationale for Adaptive or Novel Trial Design."
                        },
                        {
                          "code": "C218542",
                          "display": "ICH M11 Protocol Section 4.2.6 Rationale for Interim Analysis",
                          "definition": "The title of section 4.2.6 of the ICH M11 protocol guideline: Rationale for Interim Analysis."
                        },
                        {
                          "code": "C218543",
                          "display": "ICH M11 Protocol Section 4.2.7 Rationale for Other Trial Design Aspects",
                          "definition": "The title of section 4.2.7 of the ICH M11 protocol guideline: Rationale for Other Trial Design Aspects."
                        },
                        {
                          "code": "C218544",
                          "display": "ICH M11 Protocol Section 4.3 Trial Stopping Rules",
                          "definition": "The title of section 4.3 of the ICH M11 protocol guideline: Trial Stopping Rules."
                        },
                        {
                          "code": "C218545",
                          "display": "ICH M11 Protocol Section 4.4 Start of Trial and End of Trial",
                          "definition": "The title of section 4.4 of the ICH M11 protocol guideline: Start of Trial and End of Trial."
                        },
                        {
                          "code": "C218546",
                          "display": "ICH M11 Protocol Section 4.5 Access to Trial Intervention After End of Trial",
                          "definition": "The title of section 4.5 of the ICH M11 protocol guideline: Access to Trial Intervention After End of Trial."
                        },
                        {
                          "code": "C218547",
                          "display": "ICH M11 Protocol Section 5 TRIAL POPULATION",
                          "definition": "The title of section 5 of the ICH M11 protocol guideline: TRIAL POPULATION."
                        },
                        {
                          "code": "C218548",
                          "display": "ICH M11 Protocol Section 5.1 Description of Trial Population and Rationale",
                          "definition": "The title of section 5.1 of the ICH M11 protocol guideline: Description of Trial Population and Rationale."
                        },
                        {
                          "code": "C218549",
                          "display": "ICH M11 Protocol Section 5.2 Inclusion Criteria",
                          "definition": "The title of section 5.2 of the ICH M11 protocol guideline: Inclusion Criteria."
                        },
                        {
                          "code": "C218550",
                          "display": "ICH M11 Protocol Section 5.3 Exclusion Criteria",
                          "definition": "The title of section 5.3 of the ICH M11 protocol guideline: Exclusion Criteria."
                        },
                        {
                          "code": "C218551",
                          "display": "ICH M11 Protocol Section 5.4 Contraception",
                          "definition": "The title of section 5.4 of the ICH M11 protocol guideline: Contraception."
                        },
                        {
                          "code": "C218552",
                          "display": "ICH M11 Protocol Section 5.4.1 Definitions Related to Childbearing Potential",
                          "definition": "The title of section 5.4.1 of the ICH M11 protocol guideline: Definitions Related to Childbearing Potential."
                        },
                        {
                          "code": "C218553",
                          "display": "ICH M11 Protocol Section 5.4.2 Contraception Requirements",
                          "definition": "The title of section 5.4.2 of the ICH M11 protocol guideline: Contraception Requirements."
                        },
                        {
                          "code": "C218554",
                          "display": "ICH M11 Protocol Section 5.5 Lifestyle Restrictions",
                          "definition": "The title of section 5.5 of the ICH M11 protocol guideline: Lifestyle Restrictions."
                        },
                        {
                          "code": "C218555",
                          "display": "ICH M11 Protocol Section 5.5.1 Meals and Dietary Restrictions",
                          "definition": "The title of section 5.5.1 of the ICH M11 protocol guideline: Meals and Dietary Restrictions."
                        },
                        {
                          "code": "C218556",
                          "display": "ICH M11 Protocol Section 5.5.2 Caffeine, Alcohol, Tobacco, and Other Restrictions",
                          "definition": "The title of section 5.5.2 of the ICH M11 protocol guideline: Caffeine, Alcohol, Tobacco, and Other Restrictions."
                        },
                        {
                          "code": "C218557",
                          "display": "ICH M11 Protocol Section 5.5.3 Physical Activity Restrictions",
                          "definition": "The title of section 5.5.3 of the ICH M11 protocol guideline: Physical Activity Restrictions."
                        },
                        {
                          "code": "C218558",
                          "display": "ICH M11 Protocol Section 5.5.4 Other Activity Restrictions",
                          "definition": "The title of section 5.5.4 of the ICH M11 protocol guideline: Other Activity Restrictions."
                        },
                        {
                          "code": "C218559",
                          "display": "ICH M11 Protocol Section 5.6 Screen Failure and Rescreening",
                          "definition": "The title of section 5.6 of the ICH M11 protocol guideline: Screen Failure and Rescreening."
                        },
                        {
                          "code": "C218560",
                          "display": "ICH M11 Protocol Section 6 TRIAL INTERVENTION AND CONCOMITANT THERAPY",
                          "definition": "The title of section 6 of the ICH M11 protocol guideline: TRIAL INTERVENTION AND CONCOMITANT THERAPY."
                        },
                        {
                          "code": "C218561",
                          "display": "ICH M11 Protocol Section 6.1 Description of Investigational Trial Intervention",
                          "definition": "The title of section 6.1 of the ICH M11 protocol guideline: Description of Investigational Trial Intervention."
                        },
                        {
                          "code": "C218580",
                          "display": "ICH M11 Protocol Section 6.10 Concomitant Therapy",
                          "definition": "The title of section 6.10 of the ICH M11 protocol guideline: Concomitant Therapy."
                        },
                        {
                          "code": "C218581",
                          "display": "ICH M11 Protocol Section 6.10.1 Prohibited Concomitant Therapy",
                          "definition": "The title of section 6.10.1 of the ICH M11 protocol guideline: Prohibited Concomitant Therapy."
                        },
                        {
                          "code": "C218582",
                          "display": "ICH M11 Protocol Section 6.10.2 Permitted Concomitant Therapy",
                          "definition": "The title of section 6.10.2 of the ICH M11 protocol guideline: Permitted Concomitant Therapy."
                        },
                        {
                          "code": "C218562",
                          "display": "ICH M11 Protocol Section 6.2 Rationale for Investigational Trial Intervention Dose and Regimen",
                          "definition": "The title of section 6.2 of the ICH M11 protocol guideline: Rationale for Investigational Trial Intervention Dose and Regimen."
                        },
                        {
                          "code": "C218563",
                          "display": "ICH M11 Protocol Section 6.3 Investigational Trial Intervention Administration",
                          "definition": "The title of section 6.3 of the ICH M11 protocol guideline: Investigational Trial Intervention Administration."
                        },
                        {
                          "code": "C218564",
                          "display": "ICH M11 Protocol Section 6.4 Investigational Trial Intervention Dose Modification",
                          "definition": "The title of section 6.4 of the ICH M11 protocol guideline: Investigational Trial Intervention Dose Modification."
                        },
                        {
                          "code": "C218565",
                          "display": "ICH M11 Protocol Section 6.5 Management of Investigational Trial Intervention Overdose",
                          "definition": "The title of section 6.5 of the ICH M11 protocol guideline: Management of Investigational Trial Intervention Overdose."
                        },
                        {
                          "code": "C218566",
                          "display": "ICH M11 Protocol Section 6.6 Preparation, Storage, Handling and Accountability of Investigational Trial Intervention",
                          "definition": "The title of section 6.6 of the ICH M11 protocol guideline: Preparation, Storage, Handling and Accountability of Investigational Trial Intervention."
                        },
                        {
                          "code": "C218567",
                          "display": "ICH M11 Protocol Section 6.6.1 Preparation of Investigational Trial Intervention",
                          "definition": "The title of section 6.6.1 of the ICH M11 protocol guideline: Preparation of Investigational Trial Intervention."
                        },
                        {
                          "code": "C218568",
                          "display": "ICH M11 Protocol Section 6.6.2 Storage and Handling of Investigational Trial Intervention",
                          "definition": "The title of section 6.6.2 of the ICH M11 protocol guideline: Storage and Handling of Investigational Trial Intervention."
                        },
                        {
                          "code": "C218569",
                          "display": "ICH M11 Protocol Section 6.6.3 Accountability of Investigational Trial Intervention",
                          "definition": "The title of section 6.6.3 of the ICH M11 protocol guideline: Accountability of Investigational Trial Intervention."
                        },
                        {
                          "code": "C218570",
                          "display": "ICH M11 Protocol Section 6.7 Investigational Trial Intervention Assignment, Randomisation and Blinding",
                          "definition": "The title of section 6.7 of the ICH M11 protocol guideline: Investigational Trial Intervention Assignment, Randomisation and Blinding."
                        },
                        {
                          "code": "C218571",
                          "display": "ICH M11 Protocol Section 6.7.1 Participant Assignment to Investigational Trial Intervention",
                          "definition": "The title of section 6.7.1 of the ICH M11 protocol guideline: Participant Assignment to Investigational Trial Intervention."
                        },
                        {
                          "code": "C218572",
                          "display": "ICH M11 Protocol Section 6.7.2 Randomisation",
                          "definition": "The title of section 6.7.2 of the ICH M11 protocol guideline: Randomisation."
                        },
                        {
                          "code": "C218573",
                          "display": "ICH M11 Protocol Section 6.7.3 Measures to Maintain Blinding",
                          "definition": "The title of section 6.7.3 of the ICH M11 protocol guideline: Measures to Maintain Blinding."
                        },
                        {
                          "code": "C218574",
                          "display": "ICH M11 Protocol Section 6.7.4 Emergency Unblinding at the Site",
                          "definition": "The title of section 6.7.4 of the ICH M11 protocol guideline: Emergency Unblinding at the Site."
                        },
                        {
                          "code": "C218575",
                          "display": "ICH M11 Protocol Section 6.8 Investigational Trial Intervention Adherence",
                          "definition": "The title of section 6.8 of the ICH M11 protocol guideline: Investigational Trial Intervention Adherence."
                        },
                        {
                          "code": "C218576",
                          "display": "ICH M11 Protocol Section 6.9 Description of Noninvestigational Trial Intervention",
                          "definition": "The title of section 6.9 of the ICH M11 protocol guideline: Description of Noninvestigational Trial Intervention."
                        },
                        {
                          "code": "C218577",
                          "display": "ICH M11 Protocol Section 6.9.1 Background Trial Intervention",
                          "definition": "The title of section 6.9.1 of the ICH M11 protocol guideline: Background Trial Intervention."
                        },
                        {
                          "code": "C218578",
                          "display": "ICH M11 Protocol Section 6.9.2 Rescue Therapy",
                          "definition": "The title of section 6.9.2 of the ICH M11 protocol guideline: Rescue Therapy."
                        },
                        {
                          "code": "C218579",
                          "display": "ICH M11 Protocol Section 6.9.3 Other Noninvestigational Trial Intervention",
                          "definition": "The title of section 6.9.3 of the ICH M11 protocol guideline: Other Noninvestigational Trial Intervention."
                        },
                        {
                          "code": "C218583",
                          "display": "ICH M11 Protocol Section 7 PARTICIPANT DISCONTINUATION OF TRIAL INTERVENTION AND DISCONTINUATION OR WITHDRAWAL FROM TRIAL",
                          "definition": "The title of section 7 of the ICH M11 protocol guideline: PARTICIPANT DISCONTINUATION OF TRIAL INTERVENTION AND DISCONTINUATION OR WITHDRAWAL FROM TRIAL."
                        },
                        {
                          "code": "C218584",
                          "display": "ICH M11 Protocol Section 7.1 Discontinuation of Trial Intervention for Individual Participants",
                          "definition": "The title of section 7.1 of the ICH M11 protocol guideline: Discontinuation of Trial Intervention for Individual Participants."
                        },
                        {
                          "code": "C218585",
                          "display": "ICH M11 Protocol Section 7.1.1 Permanent Discontinuation of Trial Intervention",
                          "definition": "The title of section 7.1.1 of the ICH M11 protocol guideline: Permanent Discontinuation of Trial Intervention."
                        },
                        {
                          "code": "C218586",
                          "display": "ICH M11 Protocol Section 7.1.2 Temporary Discontinuation of Trial Intervention",
                          "definition": "The title of section 7.1.2 of the ICH M11 protocol guideline: Temporary Discontinuation of Trial Intervention."
                        },
                        {
                          "code": "C218587",
                          "display": "ICH M11 Protocol Section 7.1.3 Rechallenge",
                          "definition": "The title of section 7.1.3 of the ICH M11 protocol guideline: Rechallenge."
                        },
                        {
                          "code": "C218588",
                          "display": "ICH M11 Protocol Section 7.2 Participant Discontinuation or Withdrawal from the Trial",
                          "definition": "The title of section 7.2 of the ICH M11 protocol guideline: Participant Discontinuation or Withdrawal from the Trial."
                        },
                        {
                          "code": "C218589",
                          "display": "ICH M11 Protocol Section 7.3 Management of Loss to Follow-Up",
                          "definition": "The title of section 7.3 of the ICH M11 protocol guideline: Management of Loss to Follow-Up."
                        },
                        {
                          "code": "C218590",
                          "display": "ICH M11 Protocol Section 8 TRIAL ASSESSMENTS AND PROCEDURES",
                          "definition": "The title of section 8 of the ICH M11 protocol guideline: TRIAL ASSESSMENTS AND PROCEDURES."
                        },
                        {
                          "code": "C218591",
                          "display": "ICH M11 Protocol Section 8.1 Trial Assessments and Procedures Considerations",
                          "definition": "The title of section 8.1 of the ICH M11 protocol guideline: Trial Assessments and Procedures Considerations."
                        },
                        {
                          "code": "C218592",
                          "display": "ICH M11 Protocol Section 8.2 Screening/Baseline Assessments and Procedures",
                          "definition": "The title of section 8.2 of the ICH M11 protocol guideline: Screening/Baseline Assessments and Procedures."
                        },
                        {
                          "code": "C218593",
                          "display": "ICH M11 Protocol Section 8.3 Efficacy Assessments and Procedures",
                          "definition": "The title of section 8.3 of the ICH M11 protocol guideline: Efficacy Assessments and Procedures."
                        },
                        {
                          "code": "C218594",
                          "display": "ICH M11 Protocol Section 8.4 Safety Assessments and Procedures",
                          "definition": "The title of section 8.4 of the ICH M11 protocol guideline: Safety Assessments and Procedures."
                        },
                        {
                          "code": "C218595",
                          "display": "ICH M11 Protocol Section 8.4.1 Physical Examination",
                          "definition": "The title of section 8.4.1 of the ICH M11 protocol guideline: Physical Examination."
                        },
                        {
                          "code": "C218596",
                          "display": "ICH M11 Protocol Section 8.4.2 Vital Signs",
                          "definition": "The title of section 8.4.2 of the ICH M11 protocol guideline: Vital Signs."
                        },
                        {
                          "code": "C218597",
                          "display": "ICH M11 Protocol Section 8.4.3 Electrocardiograms",
                          "definition": "The title of section 8.4.3 of the ICH M11 protocol guideline: Electrocardiograms."
                        },
                        {
                          "code": "C218598",
                          "display": "ICH M11 Protocol Section 8.4.4 Clinical Laboratory Assessments",
                          "definition": "The title of section 8.4.4 of the ICH M11 protocol guideline: Clinical Laboratory Assessments."
                        },
                        {
                          "code": "C218599",
                          "display": "ICH M11 Protocol Section 8.4.5 Pregnancy Testing",
                          "definition": "The title of section 8.4.5 of the ICH M11 protocol guideline: Pregnancy Testing."
                        },
                        {
                          "code": "C218600",
                          "display": "ICH M11 Protocol Section 8.4.6 Suicidal Ideation and Behaviour Risk Monitoring",
                          "definition": "The title of section 8.4.6 of the ICH M11 protocol guideline: Suicidal Ideation and Behaviour Risk Monitoring."
                        },
                        {
                          "code": "C218601",
                          "display": "ICH M11 Protocol Section 8.5 Pharmacokinetics",
                          "definition": "The title of section 8.5 of the ICH M11 protocol guideline: Pharmacokinetics."
                        },
                        {
                          "code": "C218602",
                          "display": "ICH M11 Protocol Section 8.6 Biomarkers",
                          "definition": "The title of section 8.6 of the ICH M11 protocol guideline: Biomarkers."
                        },
                        {
                          "code": "C218603",
                          "display": "ICH M11 Protocol Section 8.6.1 Genetics, Genomics, Pharmacogenetics and Pharmacogenomics",
                          "definition": "The title of section 8.6.1 of the ICH M11 protocol guideline: Genetics, Genomics, Pharmacogenetics and Pharmacogenomics."
                        },
                        {
                          "code": "C218604",
                          "display": "ICH M11 Protocol Section 8.6.2 Pharmacodynamic Biomarkers",
                          "definition": "The title of section 8.6.2 of the ICH M11 protocol guideline: Pharmacodynamic Biomarkers."
                        },
                        {
                          "code": "C218605",
                          "display": "ICH M11 Protocol Section 8.6.3 Other Biomarkers",
                          "definition": "The title of section 8.6.3 of the ICH M11 protocol guideline: Other Biomarkers."
                        },
                        {
                          "code": "C218606",
                          "display": "ICH M11 Protocol Section 8.7 Immunogenicity Assessments",
                          "definition": "The title of section 8.7 of the ICH M11 protocol guideline: Immunogenicity Assessments."
                        },
                        {
                          "code": "C218607",
                          "display": "ICH M11 Protocol Section 8.8 Medical Resource Utilisation and Health Economics",
                          "definition": "The title of section 8.8 of the ICH M11 protocol guideline: Medical Resource Utilisation and Health Economics."
                        },
                        {
                          "code": "C218608",
                          "display": "ICH M11 Protocol Section 9 ADVERSE EVENTS, SERIOUS ADVERSE EVENTS, PRODUCT COMPLAINTS, PREGNANCY AND POSTPARTUM INFORMATION, AND SPECIAL SAFETY SITUATIONS",
                          "definition": "The title of section 9 of the ICH M11 protocol guideline: ADVERSE EVENTS, SERIOUS ADVERSE EVENTS, PRODUCT COMPLAINTS, PREGNANCY AND POSTPARTUM INFORMATION, AND SPECIAL SAFETY SITUATIONS."
                        },
                        {
                          "code": "C218609",
                          "display": "ICH M11 Protocol Section 9.1 Definitions",
                          "definition": "The title of section 9.1 of the ICH M11 protocol guideline: Definitions."
                        },
                        {
                          "code": "C218610",
                          "display": "ICH M11 Protocol Section 9.1.1 Definitions of Adverse Events",
                          "definition": "The title of section 9.1.1 of the ICH M11 protocol guideline: Definitions of Adverse Events."
                        },
                        {
                          "code": "C218611",
                          "display": "ICH M11 Protocol Section 9.1.2 Definitions of Serious Adverse Events",
                          "definition": "The title of section 9.1.2 of the ICH M11 protocol guideline: Definitions of Serious Adverse Events."
                        },
                        {
                          "code": "C218612",
                          "display": "ICH M11 Protocol Section 9.1.3 Definitions of Product Complaints",
                          "definition": "The title of section 9.1.3 of the ICH M11 protocol guideline: Definitions of Product Complaints."
                        },
                        {
                          "code": "C218613",
                          "display": "ICH M11 Protocol Section 9.1.3.1 Definitions of Medical Device Product Complaints",
                          "definition": "The title of section 9.1.3.1 of the ICH M11 protocol guideline: Definitions of Medical Device Product Complaints."
                        },
                        {
                          "code": "C218614",
                          "display": "ICH M11 Protocol Section 9.2 Timing and Procedures for Collection and Reporting",
                          "definition": "The title of section 9.2 of the ICH M11 protocol guideline: Timing and Procedures for Collection and Reporting."
                        },
                        {
                          "code": "C218615",
                          "display": "ICH M11 Protocol Section 9.2.1 Timing",
                          "definition": "The title of section 9.2.1 of the ICH M11 protocol guideline: Timing."
                        },
                        {
                          "code": "C218616",
                          "display": "ICH M11 Protocol Section 9.2.2 Collection Procedures",
                          "definition": "The title of section 9.2.2 of the ICH M11 protocol guideline: Collection Procedures."
                        },
                        {
                          "code": "C218617",
                          "display": "ICH M11 Protocol Section 9.2.3 Reporting",
                          "definition": "The title of section 9.2.3 of the ICH M11 protocol guideline: Reporting."
                        },
                        {
                          "code": "C218618",
                          "display": "ICH M11 Protocol Section 9.2.3.1 Regulatory Reporting Requirements",
                          "definition": "The title of section 9.2.3.1 of the ICH M11 protocol guideline: Regulatory Reporting Requirements."
                        },
                        {
                          "code": "C218619",
                          "display": "ICH M11 Protocol Section 9.2.4 Adverse Events of Special Interest",
                          "definition": "The title of section 9.2.4 of the ICH M11 protocol guideline: Adverse Events of Special Interest."
                        },
                        {
                          "code": "C218620",
                          "display": "ICH M11 Protocol Section 9.2.5 Disease-related Events or Outcomes Not Qualifying as AEs or SAEs",
                          "definition": "The title of section 9.2.5 of the ICH M11 protocol guideline: Disease-related Events or Outcomes Not Qualifying as AEs or SAEs."
                        },
                        {
                          "code": "C218621",
                          "display": "ICH M11 Protocol Section 9.3 Pregnancy and Postpartum Information",
                          "definition": "The title of section 9.3 of the ICH M11 protocol guideline: Pregnancy and Postpartum Information."
                        },
                        {
                          "code": "C218622",
                          "display": "ICH M11 Protocol Section 9.3.1 Participants Who Become Pregnant During the Trial",
                          "definition": "The title of section 9.3.1 of the ICH M11 protocol guideline: Participants Who Become Pregnant During the Trial."
                        },
                        {
                          "code": "C218623",
                          "display": "ICH M11 Protocol Section 9.3.2 Participants Whose Partners Become Pregnant During the Trial",
                          "definition": "The title of section 9.3.2 of the ICH M11 protocol guideline: Participants Whose Partners Become Pregnant During the Trial."
                        },
                        {
                          "code": "C218624",
                          "display": "ICH M11 Protocol Section 9.4 Special Safety Situations",
                          "definition": "The title of section 9.4 of the ICH M11 protocol guideline: Special Safety Situations."
                        },
                        {
                          "code": "C222770",
                          "display": "ICH M11 Protocol Section Amendment Details",
                          "definition": "The title of the amendment details section of the ICH M11 protocol guideline: Amendment Details."
                        },
                        {
                          "code": "C222769",
                          "display": "ICH M11 Protocol Section Title Page",
                          "definition": "Title Page Section of the ICH M11 Protocol standard, Title Page."
                        }
                      ]
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    }
  ]
}